Skip to main content Accessibility help
×
Home
Hostname: page-component-99c86f546-45s75 Total loading time: 2.664 Render date: 2021-12-04T00:10:37.766Z Has data issue: true Feature Flags: { "shouldUseShareProductTool": true, "shouldUseHypothesis": true, "isUnsiloEnabled": true, "metricsAbstractViews": false, "figures": true, "newCiteModal": false, "newCitedByModal": true, "newEcommerce": true, "newUsageEvents": true }

Part V - Prevention

Published online by Cambridge University Press:  15 December 2020

Jeffrey L. Saver
Affiliation:
David Geffen School of Medicine, University of Ca
Graeme J. Hankey
Affiliation:
University of Western Australia, Perth
Get access
Type
Chapter
Information
Stroke Prevention and Treatment
An Evidence-based Approach
, pp. 289 - 484
Publisher: Cambridge University Press
Print publication year: 2020

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

ACCORD Study Group et al. (2010). Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med, 362, 1575–85.Google Scholar
Blood Pressure Lowering Treatment Trialists’ Collaboration. (2003). Effects of different blood-pressure-lowering regimens on major cardiovascular events: results of prospectively-designed overviews of randomised trials. Lancet, 362, 1527–35.Google Scholar
Boan, AD, Lackland, DT, Ovbiagele, B. (2014). Lowering of blood pressure for recurrent stroke prevention. Stroke, 45, 2506–13.CrossRefGoogle ScholarPubMed
Brunström, M, Carlberg, B. (2018). Association of blood pressure lowering with mortality and cardiovascular disease across blood pressure levels: a systematic review and meta-analysis. JAMA Intern Med, 178(1), 2836.CrossRefGoogle ScholarPubMed
Collins, R, Peto, R, MacMahon, S, Hebert, P, Fiebach, NH, Eberlein, KA, et al. (1990). Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet, 335(8693), 827–38.Google ScholarPubMed
Ettehad, D, Emdin, CA, Kiran, A, Anderson, SG, Callender, T, Emberson, J, et al. (2016). Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet, 387(10022), 957–67.CrossRefGoogle ScholarPubMed
Huang, Y, Cai, X, Li, Y, Su, L, Mai, W, Wang, S, et al. (2014). Prehypertension and the risk of stroke: a meta-analysis. Neurology, 82, 1153–61.CrossRefGoogle ScholarPubMed
Kim, S, Shin, DW, Yun, JM, Hwang, Y, Park, SK, Ko, YJ, et al. (2016). Medication adherence and the risk of cardiovascular mortality and hospitalization among patients with newly prescribed antihypertensive medications. Hypertension, 67, 506–12.CrossRefGoogle ScholarPubMed
Law, MR, Morris, JK, Wald, NJ. (2009). Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ, 338, b1665. doi:10.1136/bmj.b1665.CrossRefGoogle ScholarPubMed
Lee, M, Saver, JL, Chang, B, Chang, KH, Hao, Q, Ovbiagele, B, et al. (2011). Presence of baseline prehypertension and risk of incident stroke: a meta-analysis. Neurology, 77, 13301337.CrossRefGoogle ScholarPubMed
Lee, M, Saver, JL, Hong, K-S, Hao, Q, Ovbiagele, B. (2012). Does achieving an intensive versus usual blood pressure level prevent stroke? Ann Neurol, 71, 133140.CrossRefGoogle ScholarPubMed
Liu, L, Wang, Z, Gong, L, Zhang, Y, Thhijs, L, Staessen, JA, et al. (2009). Blood pressure reduction for the secondary prevention of stroke: a Chinese trial and a systematic review of the literature. Hypertens Res, 32, 1032–40.CrossRefGoogle Scholar
MacMahon, S, Peto, R, Cutler, J. (1990). Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet, 335, 765–74.CrossRefGoogle ScholarPubMed
Perkovic, V, Rodgers, A. (2015). Redefining blood-pressure targets – SPRINT starts the marathon. N Engl J Med, 373, 2175–8.CrossRefGoogle ScholarPubMed
PROGRESS Collaborative Group. (2001). Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033–41.Google Scholar
Sardana, M, Syed, AA, Hashmath, Z, Phan, TS, Koppula, MR, Kewan, U, et al. (2017). Beta-blocker use is associated with impaired left atrial function in hypertension. J Am Heart Assoc, 6. doi:10.1161/JAHA.116.005163.CrossRefGoogle ScholarPubMed
Sipahi, I, Swaminathan, A, Natesan, V, Debanne, SM, Simon, DI, Fang, JC. (2012). Effect of antihypertensive therapy on incident stroke in cohorts with prehypertensive blood pressure levels: a meta-analysis of randomized controlled trials. Stroke, 43, 432–40.CrossRefGoogle ScholarPubMed
SPRINT MIND Investigators for the SPRINT Research Group. (2019). Effect of intensive vs standard blood pressure control on probable dementia: a randomized clinical trial. JAMA, 322, 169–70.Google Scholar
SPRINT Research Group et al. (2015). A randomized trial of intensive versus standard blood-pressure control. N Engl J Med, 373, 2103–16.Google Scholar
Sundstrom, J, Arima, H, Jackson, R, Turnbull, F, Rahimi, K, Chalmers, J, et al. (2015). Effects of blood pressure reduction in mild hypertension: a systematic review and meta-analysis. Ann Intern Med, 162, 184–91.CrossRefGoogle ScholarPubMed
Turner, GM, Calvert, M, Feltham, MG, Ryan, R, Fitzmaurice, D, Cheng, KK, et al. (2016). Under-prescribing of prevention drugs and primary prevention of stroke and transient ischaemic attack in UK general practice: a retrospective analysis. PLoS Med, 13, e1002169.CrossRefGoogle ScholarPubMed
Whelton, PK, Carey, RM, Aronow, WS, Casey, DE Jr, Collins, KJ, Dennison Himmelfarb, C, et al. (2018). 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension, 71(6), e13e115.Google Scholar
Zonneveld, TP, Richard, E, Vergouwen, MD, Nederkoorn, PJ, de Haan, R, Roos, YB, et al. (2018). Blood pressure-lowering treatment for preventing recurrent stroke, major vascular events, and dementia in patients with a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev, 7. CD007858. doi:10.1002/14651858.CD007858.pub2.Google ScholarPubMed
Acheson, J, Hutchinson, EC. (1972). Controlled trial of clofibrate in cerebral vascular disease. Atherosclerosis, 15, 177–83.CrossRefGoogle ScholarPubMed
Adams, SP, Sekhon, SS, Wright, JM. (2014). Lipid-lowering efficacy of rosuvastatin. Cochrane Database Syst Rev, 11. CD010254.Google ScholarPubMed
Adams, SP, Tsang, M, Wright, JM. (2015). Lipid-lowering efficacy of atorvastatin. Cochrane Database Syst Rev, 3. CD008226Google ScholarPubMed
Amarenco P, Kim JS, Labreuche J, et al. (2020). A comparison of two LDL cholesterol targets after ischemic stroke. N Engl J Med, 382, 9–19.CrossRefGoogle Scholar
Amarenco, P, Labreuche, J. (2009). Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. Lancet Neurol, 8, 453–63.CrossRefGoogle ScholarPubMed
Battaggia, A, Donzelli, A, Font, M, Molteni, D, Galvano, A. (2015). Clinical efficacy and safety of ezetimibe on major cardiovascular endpoints: systematic review and meta-analysis of randomized controlled trials. PLoS ONE, 10, e0124587.CrossRefGoogle ScholarPubMed
Bays, H. (2006). Statin safety: an overview and assessment of the data – 2005. Am J Cardiol, 97(suppl), 6 C–26 C.CrossRefGoogle ScholarPubMed
Bezerra, DC, Sharrett, AR, Matsushita, K, Gottesman, RF, Shibata, D, Mosley, TH Jr, et al. (2012). Risk factors for lacunar subtype in the atherosclerosis risk in Communities (ARIC) Study. Neurology, 78, 102108.CrossRefGoogle ScholarPubMed
Bhatia, M, Howard, SC, Clarke, TG, Murphy, MFG, Rothwell, PM. (2004). Apo-lipoproteins predict ischaemic stroke in patients with a previous transient ischaemic attack. Presented at the World Stroke Congress, Vancouver, Canada.Google Scholar
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2005). Efficacy and safety of cholesterol lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet, 366, 1267–78.Google Scholar
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2010). Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomized trials. Lancet, 376, 1670–81.Google Scholar
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2012). The effect of lowering LDL-cholesterol with statin therapy in people at low risk of vascular disese: meta-analysis of individual data from 27 randomised trials. Lancet, 380, 581–90.Google Scholar
Cholesterol Treatment Trialists’ (CTT) Collaboration. (2015). Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised studies. Lancet, 385, 13971405.CrossRefGoogle Scholar
Collins, R, Reith, C, Emberson, J, Armitage, J, Baigent, C, Blackwell, L, et al. (2016). Interpretation of the evidence for the efficacy and safety of statin therapy. Lancet, 388(10059), 2532–61.CrossRefGoogle ScholarPubMed
Dale, KM, Coleman, CI, Henyan, NN, Kluger, J, White, CM. (2006). Statins and cancer risk. JAMA, 295, 7480.CrossRefGoogle ScholarPubMed
Di Mascio, R, Marchioli, R, Tognoni, G. (2000). Cholesterol reduction and stroke occurrence: an overview of randomised clinical trials. Cerebrovasc Dis, 10, 8592.CrossRefGoogle Scholar
Heart Protection Study Collaborative Group. (2011). Effects on 11-year mortality and morbidity of lowering LDL cholesterol with simvastatin for about 5 years in 20,536 high-risk individuals: a randomized controlled trial. Lancet, 578, 2013–20.Google Scholar
Hopper, L, Martin, N, Abpelhamid, A, Davey Smith, G. (2015). Reduced in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 6. CD011737.CrossRefGoogle Scholar
HPS2-THRIVE Collaborative Group. (2014). Effects of extended-release niacin with laropiprant in high-risk patients. N Engl J Med, 371, 203–12.Google Scholar
HPS3/TIMI55–REVEAL Collaborative Group. (2017). Effects of anacetrapib in patients with atherosclerotic vascular disease. N Engl J Med, 377(13), 1217–27Google Scholar
Imamura, T, Doi, Y, Arima, H, Yonemoto, K, Hata, J, Kubo, M, et al. (2009). LDL-cholesterol and the development of stroke subtypes and coronary heart disease in a general Japanese population. Stroke, 40, 382–8.CrossRefGoogle Scholar
Keene, D, Price, C, Shun-Shin, MJ, Francis, DP. (2014). Effect on cardiovascular risk of high density lipoprotein targeted drug treatment niacin, fibrates, and CEPT inhibitors: meta-analysis of randomized controlled trials including 117,411 patients. BMJ, 349, 114.CrossRefGoogle Scholar
Koren-Morag, N, Tanne, D, Graff, E, Goldbourt, U, for the Bezafibrate Infarction Prevention Study Group. (2002). Low- and high-density lipoprotein cholesterol and ischemic cerebrovascular disease. The Bezafibrate Infarction Prevention Registry . Arch Int Med, 162, 993–9.CrossRefGoogle ScholarPubMed
Law, MR, Wald, NJ, Rudnicka, AR. (2003). Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease and stroke: systematic review and meta-analysis. BMJ, 326, 1423–9.CrossRefGoogle ScholarPubMed
Leppala, JM, Virtamo, J, Fogelholm, R, Albanes, D, Heinonen, OP. (1999). Different risk factors for different stroke subtypes. Stroke, 30, 2535–40.CrossRefGoogle ScholarPubMed
Lewington, S, Whitelock, G, Clarke, R, Sherliker, P, Emberson, J, Halsey, J, et al. (2007). Blood cholesterol and vascular mortality by age, sex, and blood pressure: a meta-analysis of individual data from 61 prospective studies with 55,000 vascular deaths. Lancet, 370, 1829–39.Google ScholarPubMed
Lp-PLA2 Studies Collaboration. (2010). Lipoprotein-associated phospholipase A2 and risk of coronary disease, stroke and mortality: collaborative analysis of 32 prospective studies. Lancet, 375, 1536–44.Google Scholar
Manktelow, B, Gillies, C, Potter, JF. (2002). Interventions in the management of serum lipids for preventing stroke recurrence. Cochrane Database Syst Rev, 3. CD002091. doi:10.1002/14651858.CD002091.CrossRefGoogle ScholarPubMed
McKinney, JS, Kostis, WJ. (2012). Statin therapy and risk of intracerebral hemorrhage. A meta-analysis of 31 randomized controlled trials. Stroke, 43, 2149–56.CrossRefGoogle ScholarPubMed
Nagasawa, S, Okamura, T, Iso, H, Tamakoshi, A, Yarada, M, Watanabe, M, et al. (2012). Relation between serum total cholesterol level and cardiovascular disease stratified by sex and age group: a pooled analysis of 65,594 individuals from cohort studies in Japan. J Am Heart Assoc, 1, e001974.CrossRefGoogle ScholarPubMed
Orozco-Beltran, D, Gil-Guillen, VF, Redon, J, Martin-Moreno, JM, Pallares-Carratala, V, Navarro-Perez, J, et al.; ESCARVAL Study Group. (2017). Lipid profile, cardiovascular disease and mortality in a Mediterranean high-risk population: the ESCARVAL-RISK study. PLoS One, 12(10), e0186196.CrossRefGoogle Scholar
Paciaroni, M, Hennerici, M, Agnelli, G, Bogousslavsky, J. (2007). Statins and stroke prevention. Cerebrovasc Dis, 24, 170–82.CrossRefGoogle ScholarPubMed
Peto, R, Collins, R. (2018). Trust the blinded randomized evidence that statin therapy rarely causes symptomatic side effects. Circulation, 138(15), 14991501.CrossRefGoogle ScholarPubMed
Pikula, A, Belser, AS, Wang, J, Himali, JJ, Kelly-Haynes, M, Kase, CS, et al. (2015). Lipid and lipoprotein measurement and the risk of ischemic vascular events. Framingham Study. Neurology, 84, 472–9.Google Scholar
Plehn, JF, Davis, BR, Sacks, FM, Rouleau, JL, Pfeffer, MA, Bernstein, V, et al. (1999). Reduction of stroke incidence after myocardial infarction with pravastatin: the Cholesterol and Recurrent Events (CARE) study. The CARE Investigators. Circulation, 99, 216–23.CrossRefGoogle ScholarPubMed
Preiss, D, Seshasai, SR, Welsh, P, Murphy, SA, Ho, JE, Waters, DD, et al. (2011). Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA, 305, 2556–64.CrossRefGoogle ScholarPubMed
Prospective Studies Collaboration. (1995). Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Lancet, 346, 1647–53.Google Scholar
Sabatine, MS, Giugliano, RP, Keech, AC, Honarpour, N, Wiviott, SD, Murphy, SA, et al.; FOURIER Steering Committee and Investigators. (2017). Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med, 376(18), 1713–22.CrossRefGoogle ScholarPubMed
Sabatine, MS, Wiviott, SD, Im, K, Murphy, SA, Giugliano, RP. (2018). Efficacy and safety of further lowering of low-density lipoprotein cholesterol in patients starting with very low levels: a meta-analysis. JAMA Cardiol, 3(9), 823–8.CrossRefGoogle ScholarPubMed
Sattar, N, Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomized statin trials. Lancet, 375, 735–42.CrossRefGoogle Scholar
Savarese, G, De Ferrari, GM, Rosano, GM, Perrone-Filardi, P. (2015). Safety and efficacy of ezetimibe: a meta-analysis. Int J Cardiol, 10(201), 247–52.Google Scholar
Schandelmaier, S, Briel, M, Saccilotto, R, Olu, KK, Arpagaus, A, Hemkens, LG, et al. (2017). Niacin for primary and secondary prevention of cardiovascular events. Cochrane Database Syst Rev, 6. CD009744.CrossRefGoogle ScholarPubMed
Silverman, MG, Ference, BA, Im, K, Wiviott, SD, Giugliano, RP, Grundy, SM, et al. (2016). Association between lowering ldl-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. JAMA, 316(12), 1289–97.CrossRefGoogle ScholarPubMed
Simons, LA, Simons, J, Friedlander, Y, McCallum, J. (2001). Cholesterol and other lipids predict CHD and ischaemic stroke in the elderly, but only in those below 70 years. Atherosclerosis, 159, 201–08.CrossRefGoogle ScholarPubMed
SPARCL Investigators. (2006). High-dose atorvastatin after stroke or transient ischemic attack. N Engl J Med, 355, 549–59.Google Scholar
Tanaka, T, Tomonori, O. (2012). Blood cholesterol level and risk of stroke in Community-based or Worksite cohort studies: a review of Japanese Cohort Studies in the past 20 years. Keio J Med, 81, 7988.CrossRefGoogle Scholar
Taylor, F, Huffman, MD, Macedo, AF, Moore, TH, Burke, M, Davey Smith, G, et al. (2013). Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev, 1. CD004816.Google ScholarPubMed
Teng, M, Lin, L, Zhao, YJ, Khoo, AL, Davis, BR, Yong, QW. (2015). Statins for primary prevention of cardiovascular disease in elderly patients: systematic review and meta-analysis. Drugs Aging, 32(8), 649–61.CrossRefGoogle ScholarPubMed
Thompson, PD, Clarkson, P, Karas, RH. (2003). Statin associated myopathy. JAMA, 289, 1681–90.CrossRefGoogle ScholarPubMed
van Driel, ML, Morledge, MD, Ulep, R, Shaffer, JP, Davies, P, Deichmann, R. (2016). Interventions to improve adherence to lipid-lowering medication. Cochrane Database Syst Rev, 12. CD004371.Google ScholarPubMed
Veterans Administration Cooperative Study Group. (1973). The treatment of cerebrovascular disease with Clofibrate. Final report of the Veterans Administration Cooperative Study of Atherosclerosis, Neurology Section. Stroke, 4, 684–93.Google Scholar
Wang, D, Liu, B, Tao, W, Hao, Z, Liu, M. (2015). Fibrates for secondary prevention of cardiovascular disease and stroke. Cochrane Database Syst Rev, 10. CD009580.Google ScholarPubMed
Wang, X, Dong, Y, Qi, X, Huang, C, Hou, L. (2013). Cholesterol levels and risk of hemorrhagic stroke. A systematic review and meta-analysis. Stroke, 44, 1833–9.CrossRefGoogle ScholarPubMed
White, HD, Simes, RJ, Anderson, NE, Hankey, GJ, Watson, JDG, Hunt, D, et al. (2000). Pravastatin therapy and the risk of stroke. N Engl J Med, 343, 317–26.CrossRefGoogle ScholarPubMed
Zhan, S, Tang, M, Liu, F, Xia, P, Shu, M, Wu, X. (2018). Ezetimibe for the prevention of cardiovascular disease and all-cause mortality events. Cochrane Database Syst Rev, 11. CD012502.Google ScholarPubMed
Zhang, XL, Zhu, QQ, Zhu, L, Chen, JZ, Chen, QH, Li, GN, et al. (2015). Safety and efficacy of anti-PCSK9 antibodies: a meta-analysis of 25 randomized, controlled trials. BMC Med, 13, 123. doi:10.1186/s12916.CrossRefGoogle ScholarPubMed
Zhang, Y, Tuomilehto, J, Jousilahti, P, Wang, Y, Antikainen, R, Hu, G. (2012). Total and high-density lipoprotein cholesterol and stroke risk. Stroke, 4, 1768–74.Google Scholar
Aburto, NJ, Ziolkovska, A, Hooper, L, Elliott, P, Cappuccio, FP, Meerpohl, JJ. (2013). Effect of lower sodium intake on health: systematic review and meta-analyses. BMJ, 346, f1326.CrossRefGoogle ScholarPubMed
Adebamowo, SN, Spiegelman, D, Willett, WC, Rexrode, KM. (2015). Association between intakes of magnesium, potassium, and calcium and risk of stroke: 2 cohorts of US women and updated meta-analyses. Am J Clin Nutr, 101(6), 1269–77.CrossRefGoogle ScholarPubMed
Adler, AJ, Taylor, F, Martin, N, Gottlieb, S, Taylor, RS, Ebrahim, S. (2014). Reduced dietary salt for the prevention of cardiovascular disease. Cochrane Database Syst Rev, 12. CD009217.CrossRefGoogle ScholarPubMed
Afshin, A, Micha, R, Khatibzadeh, S, Mozaffarian, D. (2014). Consumption of nuts and legumes and risk of incident ischemic heart disease, stroke, and diabetes: a systematic review and meta-analysis. Am J Clin Nutr, 100(1), 278–88.CrossRefGoogle ScholarPubMed
Anthenelli, RM, Benowitz, NL, West, R, St Aubin, L, McRae, T, Lawrence, D, et al. (2016). Neuropsychiatric safety and efficacy of varenicline, bupropion, and nicotine patch in smokers with and without psychiatric disorders (EAGLES): a double-blind, randomised, placebo-controlled clinical trial. Lancet, 387(10037), 2507–20.CrossRefGoogle ScholarPubMed
Antithrombotic Trialists, C. (2002). Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ, 324(7329), 7186.CrossRefGoogle Scholar
Antithrombotic Trialists, Collaboration, Baigent, C Blackwell, L, Collins, R, Emberson, J, Godwin, J, Peto, R, et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373(9678), 1849–60.Google Scholar
Aune, D, Giovannucci, E, Boffetta, P, Fadnes, LT, Keum, N, Norat, T, et al. (2017). Fruit and vegetable intake and the risk of cardiovascular disease, total cancer and all-cause mortality-a systematic review and dose-response meta-analysis of prospective studies. Int J Epidemiol, 46(3), 1029–56.CrossRefGoogle ScholarPubMed
Aune, D, Keum, N, Giovannucci, E, Fadnes, LT, Boffetta, P, Greenwood, DC, et al. (2016a). Nut consumption and risk of cardiovascular disease, total cancer, all-cause and cause-specific mortality: a systematic review and dose-response meta-analysis of prospective studies. BMC Med, 14(1), 207.CrossRefGoogle ScholarPubMed
Aune, D, Keum, N, Giovannucci, E, Fadnes, LT, Boffetta, P, Greenwood, DC, et al. (2016b). Whole grain consumption and risk of cardiovascular disease, cancer, and all cause and cause specific mortality: systematic review and dose-response meta-analysis of prospective studies. BMJ, 353, i2716.CrossRefGoogle ScholarPubMed
Aung, T, Halsey, J, Kromhout, D, Gerstein, HC, Marchioli, R, Tavazzi, L, et al., and Omega-3 Treatment Trialists. (2018). Associations of omega-3 fatty acid supplement use with cardiovascular disease risks: meta-analysis of 10 trials involving 77917 individuals. JAMA Cardiol, 3(3), 225–34.CrossRefGoogle ScholarPubMed
Avert Trial Collaboration Group. (2015). Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. Lancet, 386(9988), 4655.CrossRefGoogle Scholar
Baliunas, DO, Taylor, BJ, Irving, H, Roerecke, , Patra, J, Mohapatra, S, et al. (2009). Alcohol as a risk factor for type 2 diabetes: A systematic review and meta-analysis. Diabetes Care, 32(11), 2123–32.CrossRefGoogle ScholarPubMed
Bath, PM, Gray, LJ. (2005). Association between hormone replacement therapy and subsequent stroke: a meta-analysis. BMJ, 330(7487), 342.CrossRefGoogle ScholarPubMed
Bazerbachi, F, Haffar, S, Sawas, T, Vargas, EJ, Kaur, RJ, Wang, Z, et al. (2018). Fluid-filled versus gas-filled intragastric balloons as obesity interventions: a network meta-analysis of randomized trials. Obes Surg, 28(9), 2617–25.CrossRefGoogle ScholarPubMed
Benowitz, NL, Pipe, A, West, R, Hays, JT, Tonstad, S, McRae, T, et al. (2018). Cardiovascular safety of varenicline, bupropion, and nicotine patch in smokers: a randomized clinical trial. JAMA Intern Med, 178(5), 622–31.CrossRefGoogle ScholarPubMed
Bernhardt, J, Churilov, L, Ellery, F, Collier, J, Chamberlain, J, Langhorne, P, et al., and A. C. Group (2016). Prespecified dose-response analysis for A Very Early Rehabilitation Trial (AVERT). Neurology, 86(23), 2138–45.CrossRefGoogle ScholarPubMed
Bhat, VM, Cole, JW, Sorkin, JD, Wozniak, MA, Malarcher, AM, Giles, WH, et al. (2008). Dose-response relationship between cigarette smoking and risk of ischemic stroke in young women. Stroke, 39(9), 2439–43.CrossRefGoogle ScholarPubMed
Bhatnagar, A, Whitsel, LP, Ribisl, KM, Bullen, C, Chaloupka, F, Piano, MR, et al.; American Heart Association Advocacy Coordinating Committee, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Quality of Care and Outcomes Research. (2014). Electronic cigarettes: a policy statement from the American Heart Association. Circulation, 130(16), 1418–36.CrossRefGoogle ScholarPubMed
Billinger, SA, Arena, R, Bernhardt, J, Eng, JJ, Franklin, BA, Johnson, CM, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Lifestyle and Cardiometabolic Health; Council on Epidemiology and Prevention; Council on Clinical Cardiology. (2014). Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(8), 2532–53.CrossRefGoogle ScholarPubMed
Bjelakovic, G, Nikolova, D, Gluud, LL, Simonetti, RG, Gluud, C. (2012). Antioxidant supplements for prevention of mortality in healthy participants and patients with various diseases. Cochrane Database Syst Rev, 3. CD007176.Google ScholarPubMed
Boardman, HM, Hartley, L, Eisinga, A, Main, C, Roque i Figuls, M, Bonfill Cosp, X, et al. (2015). Hormone therapy for preventing cardiovascular disease in post-menopausal women. Cochrane Database Syst Rev, 3. CD002229.Google ScholarPubMed
Borek, AJ, Abraham, C, Greaves, CJ, Tarrant, M. (2018). Group-based diet and physical activity weight-loss interventions: a systematic review and meta-analysis of randomised controlled trials. Appl Psychol Health Well Being, 10(1), 6286.CrossRefGoogle ScholarPubMed
Briasoulis, A, Agarwal, V, Messerli, FH. (2012). Alcohol consumption and the risk of hypertension in men and women: a systematic review and meta-analysis. J Clin Hypertens (Greenwich), 14(11), 792–8.CrossRefGoogle ScholarPubMed
Brien, SE, Ronksley, PE, Turner, BJ Mukamal, KJ, Ghali, WA. (2011). Effect of alcohol consumption on biological markers associated with risk of coronary heart disease: systematic review and meta-analysis of interventional studies. BMJ, 342, d636.CrossRefGoogle ScholarPubMed
Brunstrom, M, Carlberg, B. (2016). Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and meta-analyses. BMJ, 352, i717.CrossRefGoogle ScholarPubMed
Cahill, K, Lindson-Hawley, N, Thomas, KH, Fanshawe, TR, Lancaster, T. (2016). Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev, 5. CD006103.Google ScholarPubMed
Cahill, K, Stevens, S, Perera, R, Lancaster, T. (2013). Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev, 5. CD009329.CrossRefGoogle ScholarPubMed
Cai, X, Wang, C, Wang, S, Cao, G, Jin, C, Yu, J, et al. (2015). Carbohydrate intake, glycemic index, glycemic load, and stroke: a meta-analysis of prospective cohort studies. Asia Pac J Public Health, 27(5), 486–96.CrossRefGoogle ScholarPubMed
Chan, WS., Ray, J, Wai, EK, Ginsburg, S, Hannah, ME, Corey, PN, et al. (2004). Risk of stroke in women exposed to low-dose oral contraceptives: a critical evaluation of the evidence. Arch Intern Med, 164(7), 741–7.CrossRefGoogle Scholar
Chang, CL, Donaghy, M, Poulter, N. (1999). Migraine and stroke in young women: case-control study. The World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. BMJ, 318(7175), 1318.CrossRefGoogle ScholarPubMed
Chang, SH, Stoll, CR, Song, J, Varela, JE, Eagon, CJ, Colditz, GA. (2014). The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003–2012. JAMA Surg, 149(3), 275–87.CrossRefGoogle ScholarPubMed
Chen, Y, Copeland, WK, Vedanthan, R, Grant, E, Lee, JE, Gu, D, et al. (2013). Association between body mass index and cardiovascular disease mortality in east Asians and south Asians: pooled analysis of prospective data from the Asia Cohort Consortium. BMJ, 347, f5446.CrossRefGoogle ScholarPubMed
Cheng, P, Huang, W, Bai, W, Wu, Y, Yu, J, Zhu, X, et al. (2015). BMI affects the relationship between long chain n-3 polyunsaturated fatty acid intake and stroke risk: a meta-analysis. Sci Rep, 5, 14161.CrossRefGoogle ScholarPubMed
Cholesterol Treatment Trialists, Kearney, PM, Blackwell, L, Collins, R, Keech, A, Simes, J, Peto, R, et al. (2008). Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. Lancet, 371(9607), 117–25.Google ScholarPubMed
Chowdhury, R, Stevens, S, Gorman, D, Pan, A, Warnakula, S, Chowdhury, S, et al. (2012). Association between fish consumption, long chain omega 3 fatty acids, and risk of cerebrovascular disease: systematic review and meta-analysis. BMJ, 345, e6698.CrossRefGoogle ScholarPubMed
D’Elia, L, Iannotta, C, Sabino, P, Ippolito, R. (2014). Potassium-rich diet and risk of stroke: updated meta-analysis. Nutr Metab Cardiovasc Dis, 24(6), 585–7.Google ScholarPubMed
D’Isabella, NT, Shkredova, DA, Richardson, JA, Tang, A. (2017). Effects of exercise on cardiovascular risk factors following stroke or transient ischemic attack: a systematic review and meta-analysis. Clin Rehabil, 31(12), 1561–72.CrossRefGoogle ScholarPubMed
de Goede, J, Soedamah-Muthu, SS, Pan, A Gijsbers, L, Geleijnse, M. (2016). Dairy consumption and risk of stroke: a systematic review and updated dose-response meta-analysis of prospective cohort studies. J Am Heart Assoc, 5(5):e002787. doi: 10.1161/JAHA.115.002787 May 20;5(5):e002787. doi: 10.1161/JAHA.115.002787.CrossRefGoogle ScholarPubMed
de Souza, RJ, Mente, A, Maroleanu, A, Cozma, AI, Ha, V, Kishibe, T, et al. (2015). Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: systematic review and meta-analysis of observational studies. BMJ, 351, h3978.CrossRefGoogle ScholarPubMed
Ding, M, Bhupathiraj, SN, Satija, A, van Dam, RM, Hu, FU. (2014). Long-term coffee consumption and risk of cardiovascular disease: a systematic review and a dose-response meta-analysis of prospective cohort studies. Circulation, 129(6), 643–59.CrossRefGoogle Scholar
Edjoc, RK, Reid, RD, Sharma, M. (2012). The effectiveness of smoking cessation interventions in smokers with cerebrovascular disease: a systematic review. BMJ Open, 2(6), e002022.CrossRefGoogle ScholarPubMed
Eisenberg, MJ, Windle, SB, Roy, N, Old, W, Grondin, FR, Bata, I, et al., and EVITA investigators. (2016). Varenicline for smoking cessation in hospitalized patients with acute coronary syndrome. Circulation, 133(1), 2130.CrossRefGoogle ScholarPubMed
Emdin, CA, Rahimi, K, Neal, B, Callender, T, Perkovic, V, Patel, A. (2015). Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. JAMA, 313(6), 603–15.CrossRefGoogle ScholarPubMed
Epstein, KA, Viscoli, CM, Spence, JD, Young, LH, Inzucchi, SE, Gorman, M, et al, and I. T. Investigators. (2017). Smoking cessation and outcome after ischemic stroke or TIA. Neurology, 89(16), 1723–9.CrossRefGoogle ScholarPubMed
Fang, X, Wang, K, Han, D, He, X, Wei, J, Zhao, L, et al. (2016). Dietary magnesium intake and the risk of cardiovascular disease, type 2 diabetes, and all-cause mortality: a dose-response meta-analysis of prospective cohort studies. BMC Med, 14(1), 210.CrossRefGoogle ScholarPubMed
Ferri, M, Amato, L, Davoli, M. (2006). Alcoholics Anonymous and other 12-step programmes for alcohol dependence. Cochrane Database Syst Rev, 3. CD005032.Google ScholarPubMed
Ford, JA, MacLennan, GS, Avenell, A, Bolland, M, Grey, A, Witham, M, et al. (2014). Cardiovascular disease and vitamin D supplementation: trial analysis, systematic review, and meta-analysis. Am J Clin Nutr, 100(3), 746–55.CrossRefGoogle Scholar
Fox, CS, Golden, SH, Anderson, C, Bray, GA, Burke, LE, de Boer, IH, et al.; American Heart Association Diabetes Committee of the Council on Lifestyle and Cardiometabolic Health; Council on Clinical Cardiology, Council on Cardiovascular and Stroke Nursing, Council on Cardiovascular Surgery and Anesthesia, Council on Quality of Care and Outcomes Research; American Diabetes Association. (2015). Update on prevention of cardiovascular disease in adults with type 2 diabetes mellitus in light of recent evidence: a scientific statement from the American Heart Association and the American Diabetes Association. Circulation, 132(8), 691718.CrossRefGoogle ScholarPubMed
Gillum, LA, Mamidipudi, SK, Johnston, SC. (2000). Ischemic stroke risk with oral contraceptives: a meta-analysis. JAMA, 284(1), 72–8.CrossRefGoogle ScholarPubMed
Greaves, CJ, Sheppard, KE, Abraham, C, Hardeman, W, Roden, M, Evans, PH, et al., I. S. Group (2011). Systematic review of reviews of intervention components associated with increased effectiveness in dietary and physical activity interventions. BMC Public Health, 11, 119.CrossRefGoogle ScholarPubMed
Guo, Y, Yue, XJ, Li, HH, Song, ZX, Yan, HQ, Zhang, P, et al. (2016). Overweight and obesity in young adulthood and the risk of stroke: a meta-analysis. J Stroke Cerebrovasc Dis, 25(12), 29953004.CrossRefGoogle ScholarPubMed
Hankey, GJ. (2017). The role of nutrition in the risk and burden of stroke: an update of the evidence. Stroke, 48(11), 3168–74.CrossRefGoogle Scholar
Harvard Women’s Health Watch (2015). DASH or Mediterranean: which diet is better for you? Harvard Women’s Health Watch, 14(9), 4.Google Scholar
He, Y, Li, Y, Chen, Y, Feng, L, Nie, Z. (2014). Homocysteine level and risk of different stroke types: a meta-analysis of prospective observational studies. Nutr Metab Cardiovasc Dis, 24(11), 1158–65.CrossRefGoogle ScholarPubMed
Hooper, L, Martin, N, Abdelhamid, A., Davey Smith, G. (2015). Reduction in saturated fat intake for cardiovascular disease. Cochrane Database Syst Rev, 6. CD011737.Google ScholarPubMed
Hopper, I, Billah, B, Skiba, M, Krum, H. (2011). Prevention of diabetes and reduction in major cardiovascular events in studies of subjects with prediabetes: meta-analysis of randomised controlled clinical trials. Eur J Cardiovasc Prev Rehabil, 18(6), 813–23.CrossRefGoogle ScholarPubMed
Hsu, CY, Chiu, SW, Hong, KS, Saver, JL, Wu, YL, Lee, JD, et al. (2018). Folic acid in stroke prevention in countries without mandatory folic acid food fortification: a meta-analysis of randomized controlled trials. J Stroke, 20(1), 99109.CrossRefGoogle ScholarPubMed
Huang, K, Liu, F, Han, X, Huang, C, Huang, J, Gu, D, et al. (2016). Association of BMI with total mortality and recurrent stroke among stroke patients: A meta-analysis of cohort studies. Atherosclerosis, 253(10), 94101.CrossRefGoogle ScholarPubMed
Hughes, JR, Stead, LF, J. Hartmann-Boyce, J, Cahill, K, Lancaster, T. (2014). Antidepressants for smoking cessation. Cochrane Database Syst Rev, 1. CD000031.Google ScholarPubMed
James, AH, Bushnell, CD, Jamison, MG, Myers, ER. (2005). Incidence and risk factors for stroke in pregnancy and the puerperium. Obstet Gynecol, 106(3), 509–16.CrossRefGoogle ScholarPubMed
Jensen, MD, Ryan, DH, Apovian, CM, Ard, JD Comuzzie, AG, Donato, KA, et al., American College of Cardiology/American Heart Association Task Force on Practice Guidelines; Obesity Society. (2014). 2013 AHA/ACC/TOS guideline for the management of overweight and obesity in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and The Obesity Society. J Am Coll Cardiol 63(25 Pt B): 29853023.CrossRefGoogle Scholar
Johnston, BC, Kanters, S, Bandayrel, K, Wu, P, Naji, F, Siemieniuk, RA, et al. (2014). Comparison of weight loss among named diet programs in overweight and obese adults: a meta-analysis. JAMA, 312(9), 923933.CrossRefGoogle ScholarPubMed
Jonas, DE, Amick, HR, Feltner, C, Bobashev, G, Thomas, K, Wines, R, et al. (2014). Pharmacotherapy for adults with alcohol use disorders in outpatient settings: a systematic review and meta-analysis. JAMA, 311(18), 1889–1900.CrossRefGoogle ScholarPubMed
Kawachi, I, Colditz, GA, Stampfer, MJ, Willett, WC, Manson, JE, Rosner, B, et al. (1993). Smoking cessation and decreased risk of stroke in women. JAMA, 269(2), 232–6.CrossRefGoogle ScholarPubMed
Kemmeren, JM, Tanis, BC, van den Bosch, MA, Bollen, EL, Helmerhorst, FM, van der Graaf, Y, et al. (2002). Risk of Arterial Thrombosis in Relation to Oral Contraceptives (RATIO) study: oral contraceptives and the risk of ischemic stroke. Stroke, 33(5), 1202–08.CrossRefGoogle ScholarPubMed
Kernan, WN, Ovbiagele, B, Black, HR, Bravata, DM, Chimowitz, MI, Ezekowitz, MD, et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(7), 21602236.CrossRefGoogle ScholarPubMed
Khoury, JC, Kleindorfer, D, Alwell, K, Moomaw, CJ, Woo, D, Adeoye, O, et al. (2013). Diabetes mellitus: a risk factor for ischemic stroke in a large biracial population. Stroke, 44(6), 1500–04.CrossRefGoogle Scholar
Kodama, S, Saito, K, Tanaka, S, Horikawa, C, Saito, A, Heianza, Y, et al. (2011). Alcohol consumption and risk of atrial fibrillation: a meta-analysis. J Am Coll Cardiol, 57(4), 427–36.CrossRefGoogle ScholarPubMed
Kwok, CS, Pradhan, A, Khan, MA, Anderson, SG, Keavney, BD, Myint, PK, et al. (2014). Bariatric surgery and its impact on cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Cardiol, 173(1), 20–8.CrossRefGoogle ScholarPubMed
Larsson, SC, Wallin, A, Wolk, A, Markus, HS. (2016). Differing association of alcohol consumption with different stroke types: a systematic review and meta-analysis. BMC Med, 14(1), 178.CrossRefGoogle ScholarPubMed
Lee, HJ, Choi, EK, Lee, SH, Kim, YJ, Han, D, Oh, S. (2018). Risk of ischemic stroke in metabolically healthy obesity: a nationwide population-based study. PLoS One, 13(3), e0195210.CrossRefGoogle ScholarPubMed
Lee, M, Saver, JL, Hong, KS, Song, S, Chang, KH, Ovbiagele, B. (2012). Effect of pre-diabetes on future risk of stroke: meta-analysis. BMJ, 344, e3564.CrossRefGoogle ScholarPubMed
Lee, PN, Forey, BA. (2006). Environmental tobacco smoke exposure and risk of stroke in nonsmokers: a review with meta-analysis. J Stroke Cerebrovasc Dis, 15(5), 190201.CrossRefGoogle ScholarPubMed
Li XY, Cai XL, Bian PD, Hu LR. (2012). High salt intake and stroke: meta-analysis of the epidemiologic evidence. CNS Neurosci Ther, 18(8), 691–701.CrossRefGoogle Scholar
Lin, MP, Ovbiagele, B, Markovic, D, Towfighi, A. (2016). Association of secondhand smoke with stroke outcomes. Stroke, 47(11), 2828–35.CrossRefGoogle ScholarPubMed
Liyanage, T, Ninomiya, T, Wang, A, Neal, B, Jun, M, Wong, MG, et al. (2016). Effects of the Mediterranean Diet on cardiovascular outcomes – a systematic review and meta-analysis. PLoS One, 11(8), e0159252.CrossRefGoogle ScholarPubMed
Lloyd-Jones, DM, Hong, Y, Labarthe, D, Mozaffarian, D, Appel, LJ, Van Horn, L, et al. (2010). Defining and setting national goals for cardiovascular health promotion and disease reduction: the American Heart Association’s strategic Impact Goal through 2020 and beyond. Circulation, 121(4), 586613.CrossRefGoogle ScholarPubMed
Malek, AM, Cushman, M, Lackland, DT, Howard, G, McClure, LA. (2015). Secondhand smoke exposure and stroke: the Reasons for Geographic and Racial Differences in Stroke (REGARDS) Study. Am J Prev Med, 49(6), e8997.CrossRefGoogle ScholarPubMed
Marso, SP, Kennedy, KF, House, JA, McGuire, DK. (2010). The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. Diab Vasc Dis Res, 7(2), 119–30.CrossRefGoogle ScholarPubMed
Marti-Carvajal, AJ, Sola, I, Lathyris, D, Dayer, M. (2017). Homocysteine-lowering interventions for preventing cardiovascular events. Cochrane Database Syst Rev, 8. CD006612.Google ScholarPubMed
Martinez-Gonzalez, MA, Dominguez, LJ, Delgado-Rodriguez, M. (2014). Olive oil consumption and risk of CHD and/or stroke: a meta-analysis of case-control, cohort and intervention studies. Br J Nutr, 112(2), 248–59.CrossRefGoogle ScholarPubMed
McRobbie, H, Bullen, C, Hartmann-Boyce, J, Hajek, P. (2014). Electronic cigarettes for smoking cessation and reduction. Cochrane Database Syst Rev, 12. CD010216.Google ScholarPubMed
Meschia, JF, Bushnell, C, Boden-Albala, B, Braun, LT, Bravata, DM, Chaturvedi, S, et al.; American Heart Association Stroke Council; Council on Cardiovascular and Stroke Nursing; Council on Clinical Cardiology; Council on Functional Genomics and Translational Biology; Council on Hypertension. (2014). Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45(12), 37543832.CrossRefGoogle ScholarPubMed
Moresoli, P, Habib, B, Reynier, P, Secrest, MH, Eisenberg, MJ, Filion, KB. (2017). Carotid stenting versus endarterectomy for asymptomatic carotid artery stenosis: a systematic review and meta-analysis. Stroke, 48(8), 2150–7.CrossRefGoogle ScholarPubMed
Mukamal, KJ, Massaro, JM, Ault, KA, Mittleman, MA, Sutherland, PA, Lipinska, I, (2005). Alcohol consumption and platelet activation and aggregation among women and men: the Framingham Offspring Study. Alcohol Clin Exp Res, 29(10), 1906–12.CrossRefGoogle ScholarPubMed
Myung, SK, Ju, W, Cho, B, Oh, SW, Park, SM, Koo, BK, Park, BJ, and Korean Meta-Analysis Study Group. (2013). Efficacy of vitamin and antioxidant supplements in prevention of cardiovascular disease: systematic review and meta-analysis of randomised controlled trials. BMJ, 346, f10.CrossRefGoogle ScholarPubMed
Narain, A, Kwok, CS, Mamas, MA. (2016). Soft drinks and sweetened beverages and the risk of cardiovascular disease and mortality: a systematic review and meta-analysis. Int J Clin Pract, 70(10), 791805.CrossRefGoogle ScholarPubMed
Ndanuko, RN, Tapsell, LC, Charlton, KE, Neale, EP, Batterham, MJ. (2016). Dietary patterns and blood pressure in adults: a systematic review and meta-analysis of randomized controlled trials. Adv Nutr, 7(1), 7689.CrossRefGoogle ScholarPubMed
Nightingale, AL, Farmer, RD. (2004). Ischemic stroke in young women: a nested case-control study using the UK General Practice Research Database. Stroke, 35(7), 1574–8.CrossRefGoogle ScholarPubMed
O’Donnell, MJ, Chin, SL, Rangarajan, S, Xavier, D, Liu, L, Zhang, H, et al.; and INTERSTROKE Investigators. (2016). Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. Lancet, 388(10046), 761–75.Google ScholarPubMed
Oesch, L, Tatlisumak, T, Arnold, M, Sarikaya, H. (2017). Obesity paradox in stroke – myth or reality? A systematic review. PLoS One, 12(3), e0171334.CrossRefGoogle ScholarPubMed
Oono, IP, Mackay, DF, Pell, JP. (2011). Meta-analysis of the association between secondhand smoke exposure and stroke. J Public Health (Oxf), 33(4), 496502.CrossRefGoogle ScholarPubMed
Pan, A, Wang, Y, Talaei, M, Hu, FB. (2015). Relation of smoking with total mortality and cardiovascular events among patients with diabetes mellitus: a meta-analysis and systematic review. Circulation, 132(19), 17951804.CrossRefGoogle ScholarPubMed
Peters, SA, Huxley, RR, Woodward, M. (2013). Smoking as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 81 cohorts, including 3,980,359 individuals and 42,401 strokes. Stroke, 44(10), 2821–8.CrossRefGoogle ScholarPubMed
Peters, SA, Huxley, RR, Woodward, M. (2014). Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775,385 individuals and 12,539 strokes. Lancet, 383(9933), 1973–80.CrossRefGoogle ScholarPubMed
Qin, X, Li, J, Spence, JD, Zhang, Y, Li, Y, Wang, X, et al. (2016). Folic acid therapy reduces the first stroke risk associated with hypercholesterolemia among hypertensive patients. Stroke, 47(11), 2805–12.CrossRefGoogle ScholarPubMed
Roach, RE, Helmerhorst, FM, Lijfering, WM, Stijnen, T, Algra, A, Dekkers, OM. (2015). Combined oral contraceptives: the risk of myocardial infarction and ischemic stroke. Cochrane Database Syst Rev, 8. CD011054.Google ScholarPubMed
Roberson, LL, Aneni, EC, Maziak, W, Agatston, A, Feldman, T, Rouseff, M, et al. (2014). Beyond BMI: the metabolically healthy obese phenotype & its association with clinical/subclinical cardiovascular disease and all-cause mortality – a systematic review. BMC Public Health, 14, 14.CrossRefGoogle ScholarPubMed
Rothwell, PM, Eliasziw, M, Gutnikov, SA, Fox, AJ, Taylor, DW, Mayberg, MR, et al. (2003). Analysis of pooled data from the randomised controlled trials of endarterectomy for symptomatic carotid stenosis. Lancet, 361(9352), 107–16.CrossRefGoogle ScholarPubMed
Sabatine, MS, Leiter, LA, Wiviott, SD, Giugliano, RP, Deedwania, P, De Ferrari, GM, et al. (2017). Cardiovascular safety and efficacy of the PCSK9 inhibitor evolocumab in patients with and without diabetes and the effect of evolocumab on glycaemia and risk of new-onset diabetes: a prespecified analysis of the FOURIER randomised controlled trial. Lancet Diabetes Endocrinol, 5(12), 941–50.CrossRefGoogle ScholarPubMed
Sackner-Bernstein, J, Kanter, D, Kaul, S. (2015). Dietary intervention for overweight and obese adults: comparison of low-carbohydrate and low-fat diets. a meta-analysis. PLoS One, 10(10), e0139817.CrossRefGoogle ScholarPubMed
Samson, JE, Tanner-Smith, EE. (2015). Single-session alcohol interventions for heavy drinking college students: a systematic review and meta-analysis. J Stud Alcohol Drugs, 76(4), 530–43.CrossRefGoogle ScholarPubMed
Santos, FL, Esteves, SS, da Costa Pereira, A, Yancy, WS Jr, Nunes, JP. (2012). Systematic review and meta-analysis of clinical trials of the effects of low carbohydrate diets on cardiovascular risk factors. Obes Rev, 13(11), 1048–66.CrossRefGoogle ScholarPubMed
Sattar, N, Preiss, D, Murray, HM, Welsh, P, Buckley, BM, de Craen, AJ, et al. (2010). Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet, 375(9716), 735–42.CrossRefGoogle ScholarPubMed
Schwingshackl, L, Bogensberger, B, Hoffmann, G. (2018). Diet quality as assessed by the Healthy Eating Index, Alternate Healthy Eating Index, Dietary Approaches to Stop Hypertension Score, and Health Outcomes: an updated systematic review and meta-analysis of cohort studies. J Acad Nutr Diet, 118(1), 74–100 e111.CrossRefGoogle ScholarPubMed
Schwingshackl, L, Hoffmann, G. (2014). Monounsaturated fatty acids, olive oil and health status: a systematic review and meta-analysis of cohort studies. Lipids Health Dis, 13, 154.CrossRefGoogle ScholarPubMed
Shah, RS, Cole, JW. (2010). Smoking and stroke: the more you smoke the more you stroke. Expert Rev Cardiovasc Ther, 8(7), 917–32.CrossRefGoogle ScholarPubMed
Shou, J, Zhou, L, Zhu, S, Zhang, X. (2015). Diabetes is an independent risk factor for stroke recurrence in stroke patients: a meta-analysis. J Stroke Cerebrovasc Dis, 24(9), 1961–8.CrossRefGoogle ScholarPubMed
Siebenhofer, A, Jeitler, K, Horvath, K, Berghold, A, Posch, N, Meschik, J, et al. (2016). Long-term effects of weight-reducing drugs in people with hypertension. Cochrane Database Syst Rev, 3. CD007654.Google ScholarPubMed
Spence, JD, Yi, Q, Hankey, GJ. (2017). B vitamins in stroke prevention: time to reconsider. Lancet Neurol, 16(9), 750–60.CrossRefGoogle ScholarPubMed
Stead, LF, Buitrago, D, Preciado, N, Sanchez, G, Hartmann-Boyce, J, Lancaster, T. (2013). Physician advice for smoking cessation. Cochrane Database Syst Rev, 5. CD000165.Google ScholarPubMed
Stead, LF, Koilpillai, P, Lancaster, T. (2015). Additional behavioural support as an adjunct to pharmacotherapy for smoking cessation. Cochrane Database Syst Rev, 10. CD009670.Google ScholarPubMed
Stead, LF, Perera, R, Bullen, C, Mant, D, Hartmann-Boyce, J, Cahill, K, et al. (2012). Nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev, 11. CD000146.Google ScholarPubMed
Strazzullo, P, D’Elia, L, Cairella, G, Garbagnati, F, Cappuccio, FP, Scalfi, L. (2010). Excess body weight and incidence of stroke: meta-analysis of prospective studies with 2 million participants. Stroke, 41(5): e418–26.CrossRefGoogle ScholarPubMed
Threapleton, DE, Greenwood, DC, Evans, CE, Cleghorn, CL, Nykjaer, C, Woodhead, C, et al. (2013). Dietary fiber intake and risk of first stroke: a systematic review and meta-analysis. Stroke, 44(5), 1360–8.Google ScholarPubMed
Tian, DY, Tian, J, Shi, CH, Song, B, Wu, J, Ji, Y, et al. (2015). Calcium intake and the risk of stroke: an up-dated meta-analysis of prospective studies. Asia Pac J Clin Nutr, 24(2), 245–52.Google ScholarPubMed
Towfighi, A, Markovic, D, Ovbiagele, B. (2012a). Current national patterns of comorbid diabetes among acute ischemic stroke patients. Cerebrovasc Dis, 33(5), 411–18.CrossRefGoogle ScholarPubMed
Towfighi, A, Markovic, D, Ovbiagele, B. (2012b). Impact of a healthy lifestyle on all-cause and cardiovascular mortality after stroke in the USA. J Neurol Neurosurg Psychiatry, 83(2), 146151.CrossRefGoogle ScholarPubMed
Towfighi, A, Ovbiagele, B. (2009). The impact of body mass index on mortality after stroke. Stroke, 40(8), 2704–08.CrossRefGoogle ScholarPubMed
Vinceti, M, Filippini, T, Crippa, A, de Sesmaisons, A, Wise, LA, Orsini, N. (2016). Meta-analysis of potassium intake and the risk of stroke. J Am Heart Assoc, 5(10), e004210.CrossRefGoogle ScholarPubMed
Wahid, A, Manek, N, Nichols, M, Kelly, P, Foster, C, Webster, P, et al. (2016). Quantifying the association between physical activity and cardiovascular disease and diabetes: a systematic review and meta-analysis. J Am Heart Assoc, 5(9).CrossRefGoogle ScholarPubMed
Whiting, DR, Guariguata, L, Weil, C, Shaw, J. (2011). IDF diabetes atlas: global estimates of the prevalence of diabetes for 2011 and 2030. Diabetes Res Clin Pract, 94(3), 311–21.CrossRefGoogle ScholarPubMed
Wilk, AI, Jensen, NM, Havighurst, TC. (1997). Meta-analysis of randomized control trials addressing brief interventions in heavy alcohol drinkers. J Gen Intern Med, 12(5), 274–83.CrossRefGoogle ScholarPubMed
Woodward, M, Lam, TH, Barzi, F, Patel, A, Gu, D, Rodgers, A, et al., and Asia Pacific Cohort Studies Collaboration. (2005). Smoking, quitting, and the risk of cardiovascular disease among women and men in the Asia-Pacific region. Int J Epidemiol, 34(5), 1036–45.Google ScholarPubMed
Wu, O, Robertson, L, Twaddle, S, Lowe, GD, Clark, P, Greaves, M, et al. (2006). Screening for thrombophilia in high-risk situations: systematic review and cost-effectiveness analysis. The Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) study. Health Technol Assess, 10(11), 1110.CrossRefGoogle ScholarPubMed
Xu, L, Lam, TH, Jiang, CQ, Zhang, WS, Zhu, F, Jin, YL, et al. (2019). Egg consumption and the risk of cardiovascular disease and all-cause mortality: Guangzhou Biobank Cohort Study and meta-analyses. Eur J Nutr, 58(2), 785–96.CrossRefGoogle ScholarPubMed
Xu, Z, Li, Y, Tang, S, Huang, X, Chen, T. (2015). Current use of oral contraceptives and the risk of first-ever ischemic stroke: a meta-analysis of observational studies. Thromb Res, 136(1), 5260.CrossRefGoogle ScholarPubMed
Yang, C, Pan, L, Sun, C, Xi, Y, Wang, L, Li, D. (2016). Red meat consumption and the risk of stroke: a dose-response meta-analysis of prospective cohort studies. J Stroke Cerebrovasc Dis, 25(5), 1177–86.CrossRefGoogle ScholarPubMed
Yuan, S, Li, X, Jin, Y, Lu, J. (2017). Chocolate consumption and risk of coronary heart disease, stroke, and diabetes: a meta-analysis of prospective studies. Nutrients, 9(7):688. doi: 10.3390/nu9070688.Google ScholarPubMed
Zhang, C, Qin, YY, Wei, X, Yu, FF, Zhou, YH, He, J. (2015). Tea consumption and risk of cardiovascular outcomes and total mortality: a systematic review and meta-analysis of prospective observational studies. Eur J Epidemiol, 30(2), 103–13.CrossRefGoogle ScholarPubMed
Zhao, M, Wu, G, Li, Y, Wang, X, Hou, FF, Xu, X, et al. (2017). Meta-analysis of folic acid efficacy trials in stroke prevention: insight into effect modifiers. Neurology, 88(19), 1830–8.CrossRefGoogle ScholarPubMed
Zhong, CK, Zhong, XY, Xu, T, Zhang, YH. (2016). Measures of abdominal adiposity and risk of stroke: a dose-response meta-analysis of prospective studies. Biomed Environ Sci, 29(1), 1223.Google ScholarPubMed
Zoungas, S, Arima, H, Gerstein, HC, Holman, RR, Woodward, M, Reaven, P, et al.; Collaborators on Trials of Lowering Glucose. (2017). Effects of intensive glucose control on microvascular outcomes in patients with type 2 diabetes: a meta-analysis of individual participant data from randomised controlled trials. Lancet Diabetes Endocrinol, 5(6), 431–7.CrossRefGoogle ScholarPubMed
ACTIVE Investigators. (2009). Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med, 360, 2066–78.Google Scholar
Albertsen, IE, Rasmussen, LH, Overvad, TF, Graungaard, T, Larsen, TB, Lip, GY. (2013). Risk of stroke or systemic embolism in atrial fibrillation patients treated with warfarin: a systematic review and meta-analysis. Stroke, 44, 1329–36.CrossRefGoogle ScholarPubMed
Alli, OO, Holmes, DR Jr. (2015). Left atrial appendage occlusion for stroke prevention. Curr Probl Cardiol, 40, 429–76.CrossRefGoogle ScholarPubMed
Almekhlafi, MA, Wilton, SB, Rabi, DM, Ghali, WA, Lorenzetti, DL, Hill, MD. (2009). Recurrent cerebral ischemia in medically treated patent foramen ovale: a meta-analysis. Neurology, 73, 8997.CrossRefGoogle ScholarPubMed
Ansell, JE, Bakhru, SH, Laulicht, BE, Steiner, SS, Grosso, M, Brown, K, et al. (2014). Use of PER977 to reverse the anticoagulant effect of edoxaban. N Engl J Med, 371, 2141–2CrossRefGoogle ScholarPubMed
Baddour, LM, Wilson, WR, Bayer, AS, Fowler, VG Jr, Tleyjeh, IM, Rybak, MJ, et al. (2015) Infective endocarditis in adults: diagnosis, antimicrobial therapy, and management of complications: a scientific statement for healthcare professionals from the American Heart Association. Circulation, 132, 1435–86.CrossRefGoogle ScholarPubMed
Bala, MM, Paszek, E, Lesniak, W, Wloch-Kopec, D, Jasinska, K, Undas, A. (2018) Antiplatelet and anticoagulant agents for primary prevention of thrombosis in individuals with antiphospholipid antibodies. Cochrane Database Syst Rev, 7, CD012534.Google ScholarPubMed
Beyer-Westendorf, J, Forster, K, Pannach, S, Ebertz, F, Gelbricht, V, Thieme, C, et al. (2014). Rates, management, and outcome of rivaroxaban bleeding in daily care: results from the Dresden NOAC registry. Blood, 124, 955962.CrossRefGoogle ScholarPubMed
Borre, ED, Goode, A, Raitz, G, Shah, B, Lowenstern, A, Chatterjee, R, et al. (2018). Predicting thromboembolic and bleeding event risk in patients with non-valvular atrial fibrillation: a systematic review. Thromb Haemost, 118, 2171–87.Google ScholarPubMed
Bruins Slot, KM, Berge, E. (2018). Factor Xa inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in patients with atrial fibrillation. Cochrane Database Syst Rev, 3, CD008980. doi:10.1002/14651858.CD008980.pub3.CrossRefGoogle ScholarPubMed
Cannon, CP, Bhatt, DL, Oldgren, J, Lip, GYH, Ellis, SG, Kimura, T, et al.; RE-DUAL PCI Steering Committee and Investigators. (2017). Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med, 377, 1513–24.CrossRefGoogle ScholarPubMed
Chandrashekhar, Y, Westaby, S, Narula, J. (2009) Mitral stenosis. Lancet, 374, 1271–83.CrossRefGoogle ScholarPubMed
Chen, LY, Norby, FL, Chamberlain, AM, MacLehose, RF, Bengtson, LG, Lutsey, PL, et al. (2019). CHA2DS2-VASc score and stroke prediction in atrial fibrillation in whites, blacks and Hispanics. Stroke, 50, 2833.CrossRefGoogle Scholar
Chi, G, Kerneis, M, Kalayci, A, Liu, Y, Mehran, R, Bode, C, et al (2018). Safety and efficacy of non-vitamin K oral anticoagulant for atrial fibrillation patients after percutaneous coronary intervention: A bivariate analysis of the PIONEER AF-PCI and RE-DUAL PCI trial. Am Heart J, 203,1724.CrossRefGoogle ScholarPubMed
Connolly, SJ, Pogue, J, Eikelboom, J, Flaker, G, Commerford, P, Franzosi, MG, et al. (2008). Benefit of oral anticoagulant over antiplatelet therapy in atrial fibrillation depends on the quality of international normalized ratio control achieved by centers and countries as measured by time in therapeutic range. Circulation, 118, 2029–37.CrossRefGoogle ScholarPubMed
Connolly, SJ, Ezekowitz, MD, Yusuf, S, Eikelboom, J, Oldgren, J, Parekh, A, et al., for the RE-LY Steering Committee and Investigators. (2009). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med, 361, 1139–51.CrossRefGoogle ScholarPubMed
Connolly, SJ, Ezekowitz, MD, Yusuf, S, Reilly, PA, Wallentin, L, for the Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators. (2010). Newly identified events in the RE-LY trial (letter to the editor). N Engl J Med, 363, 1875–6.CrossRefGoogle Scholar
Connolly, SJ, Eikelboom, JW, Ng, J, Hirsh, J, Yusuf, S, Pogue, J, et al., and the ACTIVE (Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events) Steering Committee and Investigators. (2011a). Net clinical benefit of adding clopidogrel to aspirin therapy in patients with atrial fibrillation for whom vitamin K antagonists are unsuitable. Ann Intern Med, 155, 579–86.CrossRefGoogle ScholarPubMed
Connolly, SJ, Eikelboom, J, Joyner, C, Diener, HC, Hart, R, Golitsyn, S, et al., and the AVERROES Steering Committee and Investigators. (2011b). Apixaban in patients with atrial fibrillation. N Engl J Med, 364, 806–17.CrossRefGoogle ScholarPubMed
Connolly, SJ, Milling, TJ, Eikelboom, JW, Gibson, CM, Curnutte, JT, Gold, A, et al., ANNEXA-4 Investigators. (2016). Andexanet Alfa for acute major bleeding associated with factor Xa inhibitors. N Engl J Med, 375, 1131–41.CrossRefGoogle ScholarPubMed
Connolly, SJ, Crowther, M, Eikelboom, JW, Gibson, CM, Curnutte, JT, Lawrence, JH, et al; ANNEXA-4 Investigators. (2019). Full study report of Andexanet Alfa for bleeding associated with factor Xa inhibitors. N Engl J Med, 380, 1326–35.CrossRefGoogle ScholarPubMed
Das, A, Liu, D. (2015). Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol, 4, 25.CrossRefGoogle ScholarPubMed
DeWilde, WJ, Oirbans, T, Verheugt, FW, Kelder, JC, De Smet, JP, Adriaenssens, T, et al.; WOEST Study Investigators. (2013). Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomized, controlled trial. Lancet, 381, 1107–15.CrossRefGoogle ScholarPubMed
Di Biase, L, Santangeli, P, Anselmino, M, Mohanty, P, Salvetti, I, Gili, S, et al. (2012). Does the left atrial appendage morphology correlate with the risk of stroke in patients with atrial fibrillation? Results from a multicenter study. J Am Coll Cardiol, 60, 531–8.CrossRefGoogle ScholarPubMed
Diener, HC, Eikelboom, J, Connolly, SJ, Joyner, CD, Hart, RG, Lip, GY, et al.; AVERROES Steering Committee and Investigators. (2012). Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomized trial. Lancet Neurol, 11, 225–31.CrossRefGoogle ScholarPubMed
Douketis, JD, Spyropoulos, AC, Kaatz, S, Becker, RC, Caprini, JA, Dunn, AS, et al.; BRIDGE Investigators. (2015). Perioperative bridging anticoagulation in patients with atrial fibrillation. N Engl J Med, 373, 823–33.CrossRefGoogle ScholarPubMed
Eikelboom, JW, Connolly, SJ, Brueckmann, M, Granger, CB, Kappetein, AP, Mack, MJ, et al.; RE-ALIGN Investigators. (2013). Dabigatran versus warfarin in patients with mechanical heart valves. N Engl J Med, 369, 1206–14.CrossRefGoogle ScholarPubMed
Eikelboom, JW, Quinlan, DJ, van Ryn, J, Weitz, JI. (2015). Idarucizumab: the antidote for reversal of dabigatran. Circulation, 132, 2412–22.CrossRefGoogle ScholarPubMed
European Atrial Fibrillation Trial Study Group. (1993). Secondary prevention in non-rheumatic atrial fibrillation after transient ischemic attack or minor stroke. Lancet, 342, 1255–62.Google Scholar
Freudenberger, RS, Hellkamp, AS, Halperin, JL, Poole, J, Anderson, J, Johnson, G, et al. (2007). Risk of thromboembolism in heart failure: an analysis from the Sudden Cardiac Death in Heart Failure Trial (SCD-HeFT). Circulation, 115, 2637–41.CrossRefGoogle Scholar
Friberg, L, Rosenqvist, M, Lip, GY. (2012). Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J, 33, 1500–10.CrossRefGoogle ScholarPubMed
Gibson, CM, Mehran, R, Bode, C, Halperin, J, Verheugt, FW, Wildgoose, P, et al. (2016). Prevention of bleeding in patients with atrial fibrillation undergoing PCI. N Engl J Med, 375, 2423–34.CrossRefGoogle ScholarPubMed
Giugliano, RP, Ruff, CT, Braunwald, E, Murphy, SA, Wiviott, SD, Halperin, JL, et al.; ENGAGE AF-TIMI 48 Investigators. (2013). Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 369, 2093–104.CrossRefGoogle ScholarPubMed
Giugliano, RP, Ruff, CT, Rost, NS, Silverman, S, Wiviott, SD, Lowe, C, et al.; ENGAGE AF-TIMI 48 Investigators. (2014). Cerebrovascular events in 21 105 patients with atrial fibrillation randomized to edoxaban versus warfarin: Effective Anticoagulation with Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48. Stroke, 45, 2372–8.CrossRefGoogle ScholarPubMed
Gladstone, DJ, Spring, M, Dorian, P, for the EMBRACE Investigators and Coordinators. (2014). Atrial fibrillation in patients with cryptogenic stroke. N Engl J Med, 370, 2467–77.CrossRefGoogle ScholarPubMed
Glund, S, Stangier, J, Schmohl, M, Gansser, D, Norris, S, van Ryn, J, et al. (2015). Safety, tolerability, and efficacy of idarucizumab for the reversal of the anticoagulant effect of dabigatran in healthy male volunteers: a randomised, placebo-controlled, double-blind phase 1 trial. Lancet, 386, 680–90.CrossRefGoogle ScholarPubMed
Goldberger, JJ, Arora, R, Green, D, Greenland, P, Lee, DC, Lloyd-Jones, DM, et al. (2015). Evaluating the atrial myopathy underlying atrial fibrillation: identifying the arrhythmogenic and thrombogenic substrate. Circulation, 132, 278–91.CrossRefGoogle ScholarPubMed
Goldstein, JN, Refaai, MA, Milling, TJ Jr, Lewis, B, Goldberg-Alberts, R, Hug, BA, et al. (2015). Four-factor prothrombin complex concentrate versus plasma for rapid vitamin K antagonist reversal in patients needing urgent surgical or invasive interventions: a phase 3b, open-label, non-inferiority, randomised trial. Lancet, 385, 2077–87.CrossRefGoogle ScholarPubMed
Gosselin, RC, Adcock, DM, Bates, SM, Douxfils, J, Favaloro, EJ, Gouin-Thibault, I, et al., International Council for Standardization in Haematology (ICSH). (2018). Recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost, 118, 437–50.Google ScholarPubMed
Granger, CB, Alexander, JH, McMurray, JJV, Lopes, RD, Hylek, EM, Hanna, M, et al., for the ARISTOTLE Committees and Investigators. (2011). Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med, 365, 981–92.CrossRefGoogle ScholarPubMed
Gurol, ME. (2018). Nonpharmacological management of atrial fibrillation in patients at high intracranial hemorrhage risk. Stroke, 49, 247254.CrossRefGoogle ScholarPubMed
Hankey, GJ, Patel, MR, Stevens, SR, Becker, RC, Breithardt, G, Carolei, A, et al.; ROCKET AF Steering Committee Investigators. (2012). Rivaroxaban compared with warfarin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a subgroup analysis of ROCKET AF. Lancet Neurol, 11, 315-22.CrossRefGoogle ScholarPubMed
Hankey, GJ, McQuillan, BM. (2018). Patent foramen ovale closure: the pendulum swings. Circulation, 137, 1991–3.CrossRefGoogle ScholarPubMed
Hankey, GJ, Stevens, SR, Piccini, JP, Lokhnygina, Y, Mahaffey, KW, Halperin, JL, et al.; ROCKET AF Steering Committee and Investigators. (2014). Intracranial hemorrhage among patients with atrial fibrillation anticoagulated with warfarin or rivaroxaban: the rivaroxaban once daily, oral, direct factor XA inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation. Stroke, 45, 1304–12.CrossRefGoogle ScholarPubMed
Hanif, H, Belley-Cote, EP, Alotaibi, A, Dvirnik, N, Neupane, B, Beyene, J, et al. (2018). Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. J Cardiovasc Surg (Torino), 59, 128–39.Google ScholarPubMed
Hart, RG, Diener, HC, Yang, S, Connolly, SJ, Wallentin, L, Reilly, PA, et al. (2012). Intracranial hemorrhage in atrial fibrillation patients during anticoagulation with warfarin or dabigatran: the RE-LY trial. Stroke, 43, 1511–17.CrossRefGoogle ScholarPubMed
Hart, RG, Pearce, LA, Aguilar, MI. (2007). Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med, 146, 857–67.CrossRefGoogle ScholarPubMed
Healey, JS, Eikelboom, J, Douketis, J, Wallentin, L, Oldgren, J, Yang, S, et al. (2012). Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long- Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation, 126, 343–8.CrossRefGoogle ScholarPubMed
Healey, JS, Hart, RG, Pogue, J, Pfeffer, MA, Hohnloser, SH, De Caterina, R, et al. (2008). Risks and benefits of oral anticoagulation compared with clopidogrel plus aspirin in patients with atrial fibrillation according to stroke risk: the atrial fibrillation clopidogrel trial with irbesartan for prevention of vascular events (ACTIVE-W). Stroke, 39, 1482–6.CrossRefGoogle Scholar
Heidbuchel, H, Verhamme, P, Alings, M, Antz, M, Hacke, W, Oldgren, J, et al.; European Heart Rhythm Association. (2013). European Heart Rhythm Association Practical Guide on the use of new oral anticoagulants in patients with non-valvular atrial fibrillation. Europace, 15, 625–51.CrossRefGoogle ScholarPubMed
Heidbuchel, H, Verhamme, P, Alings, M, Antz, M, Diener, HC, Hacke, W, et al.; ESC Scientific Document Group. (2017) Updated European Heart Rhythm Association practical guide on the use of non-vitamin-K antagonist anticoagulants in patients with non-valvular atrial fibrillation: executive summary. Eur Heart J, 38, 2137–49.Google ScholarPubMed
Heo, YA. (2018). Andexanet alfa: first global approval. Drugs, 78, 1049–55.Google ScholarPubMed
Hijazi, Z, Lindbäck, J, Alexander, JH, Hanna, M, Held, C, Hylek, EM, et al., for the ARISTOTLE and STABILITY Investigators. (2016a). The ABC (age, biomarkers, clinical history) stroke risk score: a biomarker-based risk score for predicting stroke in atrial fibrillation. Eur Heart J, 37, 1582–90.CrossRefGoogle ScholarPubMed
Hijazi, Z, Oldgren, J, Lindbäck, J, Alexander, JH, Connolly, SJ, Eikelboom, JW, et al., for the ARISTOTLE and RE-LY Investigators. (2016b). The novel biomarker-based ABC (age, biomarkers, clinical history)-bleeding risk score for patients with atrial fibrillation: a derivation and validation study. Lancet, 387, 2302–11.CrossRefGoogle ScholarPubMed
Homma, S, Sacco, RL, Di Tullio, MR, Sciacca, RR, Mohr, JP; PFO In Cryptogenic Stroke Study (PICSS) Investigators. (2002). Effect of medical treatment in stroke patients with patent foramen ovale: Patent foramen ovale In Cryptogenic Stroke Study. Circulation, 105, 2625–31.CrossRefGoogle ScholarPubMed
Huang, WY, Singer, DE, Wu, YL, Chiang, CE, Weng, HH, Lee, M, et al. (2018). Association of intracranial haemorrhage risk with non-vitamin K antagonist oral anticoagulant use vs aspirin use. A systematic review and meta-analysis. JAMA Neurol, 75, 1511–18.CrossRefGoogle ScholarPubMed
Idarucizumab (Praxbind) – an antidote for dabigatran. (2015). Med Lett Drugs Ther, 57, 157–8.Google Scholar
Iversen, K, Ihlemann, N, Gill, SU, Madsen, T, Elming, H, Jensen, KT, et al. (2019). Partial oral versus intravenous antibiotic treatment of endocarditis. N Engl J Med, 380, 415–24.CrossRefGoogle ScholarPubMed
Jonas, DE, Kahwati, LC, Yun, JDY, Middleton, JC, Coker-Schwimmer, M, Asher, GN. (2018). Screening for atrial fibrillation with electrocardiography: evidence report and systematic review for the US Preventive Services Task Force. JAMA, 320, 485–98.CrossRefGoogle ScholarPubMed
Kasner, SE, Swaminathan, B, Lavados, P, Sharma, M, Muir, K, Veltkamp, R, et al.; NAVIGATE ESUS Investigators. (2018). Rivaroxaban or aspirin for patent foramen ovale and embolic stroke of undetermined source: a prespecified subgroup analysis from the NAVIGATE ESUS trial. Lancet Neurol, 17, 1053–60.CrossRefGoogle ScholarPubMed
Kernan, WN, Ovbiagele, B, Black, HR, Bravata, DM, Chimowitz, MI, Ezekowitz, MD, et al. (2014). Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke, 45, 2160–236.CrossRefGoogle ScholarPubMed
Kontny, F, Dale, J, Abildgaard, U, Pedersen, TR. (1997). Randomized trial of low molecular weight heparin (dalteparin) in prevention of left ventricular thrombus formation and arterial embolism after acute anterior myocardial infarction: the Fragmin in Acute Myocardial Infarction (FRAMI) Study. J Am Coll Cardiol, 30,962–9.CrossRefGoogle ScholarPubMed
Kuijpers, T, Spencer, FA, Siemieniuk, RAC, Vandvik, PO, Otto, CM, Lytvyn, L, et al. (2018). Patent foramen ovale closure, antiplatelet therapy or anticoagulation therapy alone for management of cryptogenic stroke? A clinical practice guideline. BMJ, 362, k2515.CrossRefGoogle ScholarPubMed
Leyden, JM, Kleinig, TJ, Newbury, J, Castle, S, Cranefield, J, Anderson, CS, et al. (2013). Adelaide Stroke Incidence Study: declining stroke rates but many preventable cardioembolic strokes. Stroke, 44, 1226–31.CrossRefGoogle ScholarPubMed
Lindahl, TL, Wallstedt, M, Gustafsson, KM, Persson, E, Hillarp, A. (2015). More efficient reversal of dabigatran inhibition of coagulation by activated prothrombin complex concentrate or recombinant factor VIIa than by four-factor prothrombin complex concentrate. Thromb Res, 135, 544–7.CrossRefGoogle ScholarPubMed
Lip, GY, Nieuwlaat, R, Pisters, R, Lane, DA, Crijns, HJ. (2010). Refining clinical risk stratification for predicting stroke and thromboembolism in AF using a novel risk factor-based approach: the Euro Heart Survey on Atrial Fibrillation. Chest, 137, 263–72.CrossRefGoogle ScholarPubMed
Lowenstern, A, Al-Khatib, SM, Sharan, L, Chatterjee, R, Allen LaPointe, NM, Shah, B, et al. (2018). Interventions for preventing thromboembolic events in people with atrial fibrillation. A systematic review. Ann Intern Med, 169, 774–87.CrossRefGoogle Scholar
Lu, G, DeGuzman, FR, Hollenbach, SJ, Karbarz, MJ, Abe, K, Lee, G, et al. (2013). A specific antidote for reversal of anticoagulation by direct and indirect inhibitors of coagulation factor Xa. Nat Med, 19, 446–51.CrossRefGoogle ScholarPubMed
Mahajan, N, Ganguly, J, Simegn, M, Bhattacharya, P, Shankar, L, Madhavan, R, et al. (2010). Predictors of stroke in patients with severe systolic dysfunction in sinus rhythm: role of echocardiography. Int J Cardiol, 145, 87–9.CrossRefGoogle ScholarPubMed
Maheshwari, A, Norby, FL, Roetker, NS, Soliman, EZ, Koene, RJ, Rooney, MR, et al. (2019). Refining predictions of atrial fibrillation-related stroke using the P2- CHA2DS2-VASc score. ARIC and MESA. Circulation, 139,180–91.CrossRefGoogle Scholar
Majeed, A, Agren, A, Holmstrom, M, Bruzelius, M, Chaireti, R, Odeberg, J, et al. (2017). Management of rivaroxaban- or apixaban-associated major bleeding with prothrombin complex concentrates: a cohort study. Blood, 130,1706–12CrossRefGoogle ScholarPubMed
Mas, JL, Arquizan, C, Lamy, C, Zuber, M, Cabanes, L, Derumeaux, G, et al., and the Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. (2001). Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both. N Engl J Med, 345, 1740–6.CrossRefGoogle Scholar
Mas, JL, Derumeaux, G, Guillon, B, Massardier, E, Hosseini, H, Mechtouff, L, et al., CLOSE Investigators. (2017) Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke. N Engl J Med, 377, 1011–21.CrossRefGoogle ScholarPubMed
Massel, DR, Little, SH. (2013). Antiplatelet and anticoagulation for patients with prosthetic heart valves. Cochrane Database Syst Rev, 7, CD003464. doi:10.1002/14651858.CD003464.pub2.CrossRefGoogle ScholarPubMed
Mazzucco, S, Li, L, Binney, L, Rothwell, PM; Oxford Vascular Study Phenotyped Cohort. (2018). Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis. Lancet Neurol; 17, 609–17.CrossRefGoogle ScholarPubMed
McGrath, ER, Kapral, MK, Fang, J, Eikelboom, JW, o Conghaile, A, Canavan, M, et al., and the Investigators of the Registry of the Canadian Stroke Network. (2012). Which risk factors are more associated with ischemic stroke than intracerebral hemorrhage in patients with atrial fibrillation? Stroke, 43, 2048–54.CrossRefGoogle ScholarPubMed
Merkler, AE, Gialdini, G, Yaghi, S, Okin, PM, Iadecola, C, Navi, BB, Kamel, H. (2017). Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. Stroke, 48, 3073–7.CrossRefGoogle ScholarPubMed
Mir, H, Siemieniuk, RAC, Ge, LC, Foroutan, F, Fralick, M, Syed, T, et al (2018). Patent foramen ovale closure, antiplatelet therapy or anticoagulation in patients with patent foramen ovale and cryptogenic stroke: a systematic review and network meta-analysis incorporating complementary external evidence. BMJ Open, 8, e023761.CrossRefGoogle ScholarPubMed
Nishimura, RA, Otto, CM, Bonow, RO, Carabello, BA, Erwin, JP 3rd, Guyton, RA, et al. (2014). 2014 AHA/ACC Guideline for the Management of Patients with Valvular Heart Disease: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation, 129, 2440–92.Google Scholar
Ng, KKH, Whiteley, W. (2017). Anticoagulation timing for atrial fibrillation in acute ischemic stroke: time to reopen Pandora’s box? JAMA Neurol, 74, 1174–5.CrossRefGoogle ScholarPubMed
Ntaios, G, Papavasileiou, V, Diener, HC, Makaritsis, K, Michel, P. (2017). Nonvitamin-K-antagonist oral anticoagulants versus warfarin in patients with atrial fibrillation and previous stroke or transient ischemic attack: an updated systematic review and meta-analysis of randomized controlled trials. Int J Stroke, 12, 589–96.CrossRefGoogle ScholarPubMed
Ntaios, G, Papavasileiou, V, Sagris, D, Makaritsis, K, Vemmos, K, Steiner, T, Michel, P. (2018). Closure of patent foramen ovale versus medical therapy in patients with cryptogenic stroke or transient ischemic attack: updated systematic review and meta-analysis. Stroke, 49, 412–18.CrossRefGoogle ScholarPubMed
Oldgren, J, Alings, M, Darius, H, Diener, HC, Eikelboom, J, Ezekowitz, MD, et al., and the RE-LY Investigators. (2011). Risks for stroke, bleeding, and death in patients with atrial fibrillation receiving dabigatran or warfarin in relation to the CHADS2 score: a subgroup analysis of the RE-LY trial. Ann Intern Med, 155, 660–7.CrossRefGoogle ScholarPubMed
Olesen, JB, Lip, GY, Hansen, ML, Tolstrup, JS, Lindhardsen, J, Selmer, C, et al. (2011). Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: a nationwide cohort study. BMJ, 342, d124.CrossRefGoogle ScholarPubMed
Patel, MR, Mahaffey, KW, Garg, J, Pan, G, Singer, DE, Hacke, W, et al., for the ROCKET AF Investigators. (2011). Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med, 365, 883–91.CrossRefGoogle ScholarPubMed
Pisters, R, Lane, DA, Nieuwlaat, R, de Vos, CB, Crijns, HJ, Lip, GY. (2010). A novel user-friendly score (HAS-BLED) to assess one-year risk of major bleeding in AF patients: the Euro Heart Survey. Chest, 138, 1093–100.CrossRefGoogle Scholar
Pollack, CV Jr, Reilly, PA, Eikelboom, J, Glund, S, Verhamme, P, Bernstein, RA, et al. (2015). Idarucizumab for Dabigatran Reversal. N Engl J Med. 373, 511–20.CrossRefGoogle ScholarPubMed
Pollack, CV Jr, Reilly, PA, van Ryn, J, Eikelboom, JW, Glund, S, Bernstein, RA, et al. (2017). Idarucizumab for dabigatran reversal – full cohort analysis. N Engl J Med, 377, 431–41.CrossRefGoogle ScholarPubMed
Powers, WJ. (2018) Additional factors in considering patent foramen ovale closure to prevent recurrent ischemic stroke. JAMA Neurol, 75, 895.CrossRefGoogle ScholarPubMed
Reddy, VY, Sievert, H, Halperin, J, Doshi, SK, Buchbinder, M, Neuzil, P, et al., PROTECT AF Steering Committee and Investigators. (2014). Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. JAMA, 312, 1988–98.CrossRefGoogle ScholarPubMed
Reddy, VY, Doshi, SK, Kar, S, Gibson, DN, Price, MJ, Huber, K, et al.; PREVAIL and PROTECT AF Investigators. (2017). 5-year outcomes after left atrial appendage closure: from the PREVAIL and PROTECT AF trials. J Am Coll Cardiol, 70, 2964–75.CrossRefGoogle ScholarPubMed
Reddy, VY, Akehurst, RL, Amorosi, SL, Gavaghan, MB, Hertz, DS, Holmes, DR Jr. (2018). Cost-effectiveness of left atrial appendage closure with the WATCHMAN device compared with warfarin or non-vitamin K antagonist oral anticoagulants for secondary prevention in nonvalvular atrial fibrillation. Stroke, 49, 1464–70.CrossRefGoogle ScholarPubMed
Ruff, CT, Giugliano, RP, Braunwald, E, Hoffman, EB, Deenadayalu, N, Ezekowitz, MD, et al. (2014). Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet, 383, 955–62.CrossRefGoogle ScholarPubMed
Ruff, CT, Giugliano, RP, Braunwald, E, Morrow, DA, Murphy, SA, Kuder, JF, et al. (2015). Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet, 385, 2288–95.CrossRefGoogle ScholarPubMed
Sahay, S, Nombela-Franco, L, Rodes-Cabau, J, Jimenez-Quevedo, P, Salinas, P, Biagioni, C, et al. (2017). Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. Heart, 103, 139–47.CrossRefGoogle ScholarPubMed
Salazar, CA, del Aguila, D, Cordova, EG. (2014). Direct thrombin inhibitors versus vitamin K antagonists for preventing cerebral or systemic embolism in people with non-valvular atrial fibrillation. Cochrane Database Syst Rev, 3, CD009893. doi:10.1002/14651858.CD009893.pub2.CrossRefGoogle ScholarPubMed
Sanna, T, Diener, HC, Passman, RS, Di Lazzaro, V, Bernstein, RA, Morillo, CA, et al., for the CRYSTAL AF Investigators. (2014). Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med, 370, 2478–86.CrossRefGoogle ScholarPubMed
Sarode, R, Milling, TJ Jr, Refaai, MA, Mangione, A, Schneider, A, Durn, BL, et al. (2013). Efficacy and safety of a 4-factor prothrombin complex concentrate in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. Circulation, 128, 1234–43.CrossRefGoogle ScholarPubMed
Sartori, M, Cosmi, B. (2018). Andexanet alfa to reverse the anticoagulant activity of factor Xa inhibitors: a review of design, development and potential place in therapy. J Thromb Thrombolysis, 45, 345–52.CrossRefGoogle ScholarPubMed
Saver, JL, Mattle, HP, Thaler, D. (2018). Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review. Stroke, 49, 1541–8.Google ScholarPubMed
Saxena, R, Koudstaal, PJ. (2004a). Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack. Cochrane Database Syst Rev, 2, CD000185.Google ScholarPubMed
Saxena, R, Koudstaal, PJ. (2004b). Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack. Cochrane Database Syst Rev, 4, CD000187.Google ScholarPubMed
Schneider, B, Bauer, R. (2005). Is surgical closure of patent foramen ovale the gold standard for treating interatrial shunts? An echocardiographic follow-up study. J Am Soc Echocardiogr, 18, 1385–91.CrossRefGoogle ScholarPubMed
Seiffge, DJ, Werring, DJ, Paciaroni, M, Dawson, J, Warach, S, Milling, TJ, et al. (2019). Timing of anticoagulation after recent ischaemic stroke in patients with atrial fibrillation. Lancet Neurol, 18, 117–26.CrossRefGoogle ScholarPubMed
Siegal, DM, Curnutte, JT, Connolly, SJ, Lu, G, Conley, PB, Wiens, BL, et al. (2015). Andexanet alfa for the reversal of factor Xa inhibitor activity. N Engl J Med, 373, 2413–24.CrossRefGoogle ScholarPubMed
Song, Y, Wang, Z, Perlstein, I, Wang, J, LaCreta, F, Frost, RJA, Frost, C. (2017). Reversal of apixaban anticoagulation by four-factor prothrombin complex concentrates in healthy subjects: a randomized three-period crossover study. J Thromb Haemost, 15, 2125–37.CrossRefGoogle ScholarPubMed
SPIRIT Trial Investigators. (1997). A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Ann Neurol, 43, 857–65.Google Scholar
Sposato, LA, Cipriano, LE, Saposnik, G, Ruíz Vargas, E, Riccio, PM, Hachinski, V. (2015). Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. Lancet Neurol, 14, 377–87.CrossRefGoogle ScholarPubMed
Steffel, J, Verhamme, P, Potpara, TS, Albaladejo, P, Antz, M, Desteghe, L, et al.; ESC Scientific Document Group. (2018). The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J, 39, 1330–93.CrossRefGoogle ScholarPubMed
Steiner, T, Poli, S, Griebe, M, Husing, J, Hajda, J, Freiberger, A, et al. (2016). Fresh frozen plasma versus prothrombin complex concentrate in patients with intracranial haemorrhage related to vitamin K antagonists (INCH): a randomised trial. Lancet Neurol, 15, 566–73.CrossRefGoogle ScholarPubMed
Turc, G, Calvet, D, Guérin, P, Sroussi, M, Chatellier, G, Mas, JL; CLOSE Investigators. (2018). Closure, anticoagulation, or antiplatelet therapy for cryptogenic stroke with patent foramen ovale: systematic review of randomized trials, sequential meta-analysis, and new insights from the CLOSE Study. J Am Heart Assoc, 7, pii: e008356.CrossRefGoogle ScholarPubMed
Uphaus, T, Weber-Kruger, M, Grond, M, Toenges, G, Jahn-Eimermacher, A, Jauss, M, et al. (2019). Development and validation of a score to detect paroxysmal atrial fibrillation. Neurology, 92, e115e124.CrossRefGoogle ScholarPubMed
US Preventive Services Task Force, Curry, SJ, Krist, AH, Owens, DK, Barry, MJ, Caughey, AB, Davidson, KW, et al. (2018). Screening for atrial fibrillation with electrocardiography: US Preventive Services Task Force Recommendation Statement. JAMA, 320, 478–84Google ScholarPubMed
Vaitkus, PT, Barnathan, ES. (1993). Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. J Am Coll Cardiol, 22, 1004–9.CrossRefGoogle ScholarPubMed
Verheugt, FW, Granger, CB. (2015). Oral anticoagulants for stroke prevention in atrial fibrillation: current status, special situations, and unmet needs. Lancet, 386, 303–10.CrossRefGoogle ScholarPubMed
Wang, A, Gaca, JG, Chu, VH. (2018). Management considerations in infective endocarditis: a review. JAMA, 320, 7283.CrossRefGoogle ScholarPubMed
Warkentin, TE, Margetts, P, Connolly, SJ, Lamy, A, Ricci, C, Eikelboom, JW. (2012). Recombinant factor VIIa (rFVIIa) and hemodialysis to manage massive dabigatran-associated postcardiac surgery bleeding. Blood, 119, 2172–4.CrossRefGoogle ScholarPubMed
Wilson, D, Ambler, G, Shakeshaft, C, Brown, MM, Charidimou, A, Al-Shahi Salman, R, et al.; CROMIS-2 collaborators. (2018). Cerebral microbleeds and intracranial haemorrhage risk in patients anticoagulated for atrial fibrillation after acute ischaemic stroke or transient ischaemic attack (CROMIS-2): a multicentre observational cohort study. Lancet Neurol, 17, 539–47.CrossRefGoogle ScholarPubMed
Amarenco, P, Davis, S, Jones, EF, Cohen, AA, Heiss, WD, Kaste, M, et al.; Aortic Arch Related Cerebral Hazard Trial Investigators. (2014). Clopidogrel plus aspirin versus warfarin in patients with stroke and aortic arch plaques. Stroke, 45, 1248–57CrossRefGoogle ScholarPubMed
Anand, SS, Bosch, J, Eikelboom, JW, Connolly, SJ, Diaz, R, Widimsky, P, et al.; COMPASS Investigators. (2018). Rivaroxaban with or without aspirin in patients with stable peripheral or carotid artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, 391, 219–29.CrossRefGoogle ScholarPubMed
Antithrombotic Trialists’ (ATT) Collaboration, Baigent, C, Blackwell, L, Collins, R, Emberson, J, Godwin, J, Peto, R, et al. (2009). Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet, 373, 1849–60.Google ScholarPubMed
Bhatt, DL, Fox, KA, Hacke, W, Berger, PB, Black, HR, Boden, WE, et al.; CHARISMA Investigators. (2006). Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med, 354,1706–17CrossRefGoogle ScholarPubMed
Bhatt, DL, Paré, G, Eikelboom, JW, Simonsen, KL, Emison, ES, Fox, KA, et al.; CHARISMA Investigators. (2012). The relationship between CYP2C19 polymorphisms and ischaemic and bleeding outcomes in stable outpatients: the CHARISMA genetics study. Eur Heart J, 33, 2143–50.CrossRefGoogle ScholarPubMed
Bousser, MG, Amarenco, P, Chamorro, A, Fisher, M, Ford, I, Fox, KM, et al., for the PERFORM Study Investigators. (2011). Terutroban versus aspirin in patients with cerebral ischaemic events (PERFORM): a randomised, double-blind, parallel-group trial. Lancet, 377, 2013–22. Erratum in: Lancet, 378, 402.CrossRefGoogle ScholarPubMed
CAPRIE Steering Committee. (1996) A randomised, blinded trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet, 348, 1329–39.Google Scholar
Costa, J, Ferro, J, Matias-Guiu, J, Alvarez-Sabin, J, Torres, F. (2005). Triflusal for preventing serious vascular events in people at high risk. Cochrane Database Syst Rev, 3. CD004296.Google ScholarPubMed
De Schryver, ELLM, Algra, A, vanGijn, J. (2007). Dipyridamole for preventing stroke and other vascular events in patients with vascular disease. Cochrane Database Syst Rev, 3. CD001820. doi:10.1002/14651858.CD001820.pub3.CrossRefGoogle ScholarPubMed
De Schryver, ELLM, Algra, A, Kappelle, LJ, van Gijn, J, Koudstaal, PJ. (2012). Vitamin K antagonists versus antiplatelet therapy after transient ischaemic attack or minor ischaemic stroke of presumed arterial origin. Cochrane Database Syst Rev, 9. CD001342. doi:10.1002/14651858.CD001342.pub3.CrossRefGoogle ScholarPubMed
Diener, HC, Bogousslavsky, J, Brass, LM, Cimminiello, C, Csiba, L, Kaste, M, et al.; MATCH Investigators. (2004). Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet, 364, 331–7.CrossRefGoogle ScholarPubMed
Diener, HC, Cunha, L, Forbes, C, Sivenius, J, Smets, P, Lowenthal, A. (1996). European Stroke Prevention Study. 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci, 143, 1-13.CrossRefGoogle ScholarPubMed
Diener, HC, Easton, JD, Granger, CB, Cronin, L, Duffy, C, Cotton, D, et al.; RE-SPECT ESUS Investigators. (2015). Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS). Int J Stroke, 10, 1309–12.CrossRefGoogle Scholar
Dinicolantonio, JJ, Lavie, CJ, Fares, H, Menezes, AR, O’Keefe, JH, Bangalore, S, et al. (2013). Meta-analysis of cilostazol versus aspirin for the secondary prevention of stroke. Am J Cardiol, 112, 1230–4.CrossRefGoogle ScholarPubMed
Donadini, MP, Bellesini, M, Squizzato, A. (2018). Aspirin plus clopidogrel vs aspirin alone for preventing cardiovascular events among patients at high risk for cardiovascular events. JAMA, 320, 593–4. doi:10.1001/jama.2018.9641.CrossRefGoogle ScholarPubMed
Eikelboom, JW, Connolly, SJ, Bosch, J, Dagenais, GR, Hart, RG, Shestakovska, O, et al.; COMPASS Investigators. (2017). Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med, 377, 1319–30.CrossRefGoogle ScholarPubMed
Gotoh, F, Tohgi, H, Hirai, S, Terashi, A, Fukuuchi, Y, Otomo, E, et al. (2000). Cilostazol Stroke Prevention Study: a placebo-controlled double-blind trial for secondary prevention of cerebral infarction. J Stroke Cerebrovasc Dis, 9, 147–57.CrossRefGoogle ScholarPubMed
Gouya, G, Arrich, J, Wolzt, M, Huber, K, Verheugt, FW, Gurbel, PA, et al. (2014). Antiplatelet treatment for prevention of cerebrovascular events in patients with vascular diseases: a systematic review and meta-analysis. Stroke, 45, 492503.CrossRefGoogle ScholarPubMed
Halkes, PH, Gray, LJ, Bath, PM, Diener, HC, Guiraud-Chaumeil, B, Yatsu, FM, et al. (2008). Dipyridamole plus aspirin versus aspirin alone in secondary prevention after TIA or stroke: a meta-analysis by risk. J Neurol Neurosurg Psychiatry, 79, 1218–23.CrossRefGoogle ScholarPubMed
Hankey, GJ, Johnston, SC, Easton, JD, Hacke, W, Mas, JL, Brennan, D, et al.; CHARISMA Trial Investigators. (2011). Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke, 6, 39.CrossRefGoogle ScholarPubMed
Hart, RG, Sharma, M, Mundl, H, Kasner, SE, Bangdiwala, SI, Berkowitz, SD, et al.; NAVIGATE ESUS Investigators. (2018) Rivaroxaban for stroke prevention after embolic stroke of undetermined source. N Engl J Med, 378, 21912201.CrossRefGoogle ScholarPubMed
Hilkens, NA, Algra, A, Kappelle, LJ, Bath, PM, Csiba, L, Rothwell, PM, Greving, JP; CAT Collaboration. (2018a). Early time course of major bleeding on antiplatelet therapy after TIA or ischemic stroke. Neurology, 90, e683–9.CrossRefGoogle ScholarPubMed
Hilkens, NA, Algra, A, Diener, HC, Reitsma, JB, Bath, PM, Csiba, L, et al.; Cerebrovascular Antiplatelet Trialists’ Collaborative Group. (2017). Predicting major bleeding in patients with noncardioembolic stroke on antiplatelets: S2TOP-BLEED. Neurology, 89, 936–43.CrossRefGoogle ScholarPubMed
Hilkens, NA, Li, L, Rothwell, PM, Algra, A, Greving, JP. (2018b). External validation of risk scores for major bleeding in a population-based cohort of transient ischemic attack and ischemic stroke patients. Stroke, 49, 601–06.CrossRefGoogle Scholar
Huang, WY, Singer, DE, Wu, YL, Chiang, CE, Weng, HH, Lee, M, Ovbiagele, B. (2018). Association of intracranial hemorrhage risk with non-vitamin K antagonist oral anticoagulant use vs aspirin use: a systematic review and meta-analysis. JAMA Neurol, 75(12), 1511–18. doi:10.1001/jamaneurol.2018.2215.CrossRefGoogle ScholarPubMed
Kamal, AK, Naqvi, I, Husain, MR, Khealani, BA. (2011). Cilostazol versus aspirin for secondary prevention of vascular events after stroke of arterial origin. Cochrane Database Syst Rev, 1. CD008076. doi:10.1002/14651858.CD008076.pub2.CrossRefGoogle ScholarPubMed
Kim, BJ, Lee, E-J, Kwon, SU, Park, JH, Kim, YJ, Hong, KS, et al. (2018). Prevention of cardiovascular events in Asian patients with ischaemic stroke at high risk of cerebral haemorrhage (PICASSO): a multicentre, randomised controlled trial. Lancet Neurol, 17, 509–18.CrossRefGoogle ScholarPubMed
Kwok, CS, Shoamanesh, A, Copley, HC, Myint, PK, Loke, YK, Benavente, OR. (2015). Efficacy of antiplatelet therapy in secondary prevention following lacunar stroke: pooled analysis of randomized trials. Stroke, 46, 1014–23.CrossRefGoogle ScholarPubMed
Leonardi-Bee, J, Bath, PM, Bousser, MG, Davalos, A, Diener, HC, Guiraud-Chaumeil, B, et al.; Dipyridamole in Stroke Collaboration (DISC). (2005). Dipyridamole for preventing recurrent ischemic stroke and other vascular events: a meta-analysis of individual patient data from randomized controlled trials. Stroke, 36, 162–8.CrossRefGoogle ScholarPubMed
Markus, HS, Levi, C, King, A, Madigan, J, Norris, J; Cervical Artery Dissection in Stroke Study (CADISS) Investigators. (2019). Antiplatelet therapy vs anticoagulation therapy in cervical artery dissection: the Cervical Artery Dissection in Stroke Study (CADISS) Randomized Clinical Trial Final Results. JAMA Neurol, 76, 657-64.CrossRefGoogle ScholarPubMed
McDonough, CW, McClure, LA, Mitchell, BD, Gong, Y, Horenstein, RB, Lewis, JP, et al. (2015). CYP2C19 metabolizer status and clopidogrel efficacy in the Secondary Prevention of Small Subcortical Strokes (SPS3) study. JAHA, 4, e001652.CrossRefGoogle ScholarPubMed
Morrow, DA, Alberts, MJ, Mohr, JP, Ameriso, SF, Bonaca, MP, Goto, S, Hankey, GJ, et al.; Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events–TIMI 50 Steering Committee and Investigators. (2013). Efficacy and safety of vorapaxar in patients with prior ischemic stroke. Stroke, 44, 691–8.CrossRefGoogle ScholarPubMed
Ogawa, A, Toyoda, K, Kitagawa, K, Kitazono, T, Nagao, T, Yamagami, H, et al. (2019). Comparison of prasugrel and clopidogrel in patients with non-cardioembolic ischaemic stroke: the PRASTRO-I randomised trial. Lancet Neurol, 18, 238–47.CrossRefGoogle Scholar
Roe, MT, Armstrong, PW, Fox, KA, White, HD, Prabhakaran, D, Goodman, SG, et al. (2012). Prasugrel versus clopidogrel for acute coronary syndromes without revascularization. N Engl J Med, 367, 1297–309.CrossRefGoogle ScholarPubMed
Rothwell, PM, Algra, A, Chen, Z, Diener, HC, Norrving, B, Mehta, Z. (2016). Effects of aspirin on risk and severity of early recurrent stroke after transient ischaemic attack and ischaemic stroke: time-course analysis of randomised trials. Lancet, 388, 365–75CrossRefGoogle ScholarPubMed
Rothwell, PM, Cook, NR, Gaziano, JM, Price, JF, Belch, JFF, Roncaglioni, MC, et al. (2018). Effects of aspirin on risks of vascular events and cancer according to bodyweight and dose: analysis of individual patient data from randomised trials. Lancet, 392, 387–99.CrossRefGoogle ScholarPubMed
Sacco, RL, Diener, H-C, Yusuf, S, Cotton, D, Ounpuu, S, Lawton, WA, et al. (2008). Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. The Prevention Regimen for Effectively Avoiding Second Strokes (PRoFESS) trial. N Engl J Med, 359, 1238–51.CrossRefGoogle Scholar
Sandercock, PAG, Gibson, LM, Liu, M. (2009). Anticoagulants for preventing recurrence following presumed non-cardioembolic ischaemic stroke or transient ischaemic attack. Cochrane Database Syst Rev, 2. CD000248. doi:10.1002/14651858.CD000248.pub2.CrossRefGoogle ScholarPubMed
Sharma, M, Hart, RG, Connolly, S, Bosch, J, Shestakovska, O, Ng, KH, et al. (2019). Stroke Outcomes in the Cardiovascular OutcoMes for People using Anticoagulation StrategieS (COMPASS) trial. Circulation, 139(9), 1134–45. doi 10.1161/CIRCULATIONAHA.118.035864.Google ScholarPubMed
SPS3 Investigators, Benavente, OR, Hart, RG, McClure, LA, Szychowski, JM, Coffey, CS, Pearce, LA. (2012). Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med, 367, 817–25.Google ScholarPubMed
Squizzato, A, Bellesini, M, Takeda, A, Middeldorp, S, Donadini, MP. (2017). Clopidogrel plus aspirin versus aspirin alone for preventing cardiovascular events. Cochrane Database Syst Rev, 12. CD005158.Google ScholarPubMed
Sudlow, CLM, Mason, G, Maurice, JB, Wedderburn, CJ, Hankey, GJ. (2009). Thienopyridine derivatives versus aspirin for preventing stroke and other serious vascular events in high vascular risk patients. Cochrane Database Syst Rev, 4. CD001246. doi:10.1002/14651858.CD001246.pub2.CrossRefGoogle ScholarPubMed
Topol, EJ, Easton, D, Harrington, RA, Amarenco, P, Califf, RM, Graffagnino, C, et al.; Blockade of the Glycoprotein IIb/IIIa Receptor to Avoid Vascular Occlusion Trial Investigators. (2003). Randomized, double-blind, placebo-controlled, international trial of the oral IIb/IIIa antagonist lotrafiban in coronary and cerebrovascular disease. Circulation, 108, 399406.CrossRefGoogle ScholarPubMed
Toyoda, K, Uchiyama, S, Yamaguchi, T, Easton, JD, Kimura, K, Hoshino, H, et al., for the CSPS.com Trial Investigators. (2019). Dual antiplatelet therapy using cilostazol for secondary prevention in high-risk ischaemic stroke: a multicentre randomised controlled trial. Lancet Neurol, 18(6), 539–48.CrossRefGoogle Scholar
Wiviott, SD, Braunwald, E, McCabe, CH, Montalescot, G, Ruzyllo, W, Gottlieb, S, et al. (2007). Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med, 357, 2001–15.CrossRefGoogle ScholarPubMed
Alberts, MJ. (2001). Results of a multicentre prospective randomized trial of carotid artery stenting vs. carotid endarterectomy. Stroke, 32, 325.Google Scholar
Barbato, JE, Dillavou, E, Horowitz, MB, Jovin, TG, Kanal, E. (2008). A randomized trial of carotid artery stenting with and without cerebral protection. J Vasc Surg, 47, 760–5. doi:10.1016/j.jvs.2007.11.058.CrossRefGoogle ScholarPubMed
Bijuklic, K, Wandler, A, Hazizi, F, Schofer, J. (2012). The PROFI study (prevention of cerebral embolization by proximal balloon occlusion compared to filter protection during carotid artery stenting): a prospective randomized trial. J Am Coll Cardiol, 59, 1383–9.CrossRefGoogle ScholarPubMed
Bonati, LH, Dobson, J, Featherstone, RL, Ederle, J, van der Worp, HB, de Borst, GJ, et al.; International Carotid Stenting Study Investigators. (2015). Long-term outcomes after stenting versus endarterectomy for treatment of symptomatic carotid stenosis: the International Carotid Stenting Study (ICSS) randomised trial. Lancet 385: 529538CrossRefGoogle ScholarPubMed
Bonati, LH, Jongen, LM, Haller, S, Flach, HZ, Dobson, J, Nederkoorn, PJ, et al. (2010). New ischaemic brain lesions on MRI after stenting or endarterectomy for symptomatic carotid stenosis: a substudy of the International Carotid Stenting Study (ICSS). Lancet Neurol, 9, 353–62.CrossRefGoogle Scholar
Bonati, LH, Lyrer, P, Ederle, J, Featherstone, R, Brown, MM. (2012). Percutaneous transluminal balloon angioplasty and stenting for carotid artery stenosis. Cochrane Database Syst Rev, 9. CD000515. doi:10.1002/14651858.CD000515.pub4.CrossRefGoogle ScholarPubMed
Bond, R, Rerkasem, K, Rothwell, PM. (2003). A systematic review of the risks of carotid endarterectomy in relation to the clinical indication and the timing of surgery. Stroke, 34, 22902301.CrossRefGoogle ScholarPubMed
Brooks, WH, Jones, MR, Gisler, P, McClure, RR, Coleman, TC, Breathitt, L, et al. (2014). Carotid angioplasty with stenting versus endarterectomy: 10-year randomized trial in a community hospital. JACC, 7. 163–8.Google Scholar
Brott, TG, Hobson, RW, Howard, G, Roubin, GS, Clark, WM, Brooks, W, et al. (2010). Stenting versus endarterectomy for treatment of carotid-artery stenosis. N Engl J Med, 363, 1123.CrossRefGoogle ScholarPubMed
Brott, TG, Howard, G, Roubin, GS, Meschia, JF, Mackey, A, Brooks, W, et al. (2016). Long-term results of stenting versus endarterectomy for carotid-artery stenosis. N Engl J Med, 374, 1021–31.CrossRefGoogle ScholarPubMed
Bulbulia, R, Halliday, A. (2013). ACST-2 – an update. A large, simple randomised trial to compare carotid endarterectomy versus carotid artery stenting to prevent stroke in asymptomatic patients. Gefasschirurgie, 18, 626–32.Google Scholar
Cao, PG, De Rango, P, Zannetti, S, Giordano, G, Ricci, S, Celani, MG . (2001). Eversion versus conventional carotid endarterectomy for preventing stroke. Cochrane Database Syst Rev, 1. CD001921.Google Scholar
CAVATAS Investigators. (2001). Endovascular versus surgical treatment in patients with carotid stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomised trial. Lancet, 357, 1729–37.Google Scholar
Cheng, SF, Brown, MM. (2017). Contemporary medical therapies of atherosclerotic carotid artery disease. Semin Vasc Surg, 30, 816CrossRefGoogle ScholarPubMed
Cheng, SF, Brown, MM, Simister, RJ, Richards, T. (2019). Contemporary prevalence of carotid stenosis in patients presenting with ischaemic stroke. Br J Surg, 106, 872–8.CrossRefGoogle ScholarPubMed
Chimowitz, MI, Lynn, MJ, Derdeyn, CP, Turan, TN, Fiorella, D, Lane, BF, et al. (2011). Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med, 365, 9931003.CrossRefGoogle ScholarPubMed
Chongruksut, W, Vaniyapong, T, Rerkasem, K. (2014). Routine or selective carotid artery shunting for carotid endarterectomy (and different methods of monitoring in selective shunting). Cochrane Database Syst Rev, 6. CD000190. doi:10.1002/14651858.CD000190.pub3.CrossRefGoogle Scholar
Compter, A, van der Worp, HB, Schonewille, WJ, Schonewille, WJ, Vos, JA, Boiten, J, et al; VAST Investigators. (2015). Stenting versus medical treatment in patients with symptomatic vertebral artery stenosis: a randomised open-label phase 2 trial. Lancet Neurol, 14, 606–14.CrossRefGoogle ScholarPubMed
Coull, AJ, Lovett, JK, Rothwell, PM, on behalf of the Oxford Vascular Study. (2004). Population based study of early risk of stroke after transient ischemic attack or minor stroke: implications for public education and organisation of services. BMJ, 328, 326–8.CrossRefGoogle ScholarPubMed
Coward, LJ, McCabe, DJ, Ederle, J, Featherstone, RL, Clifton, A, Brown, MM; CAVATAS Investigators. (2007). Long-term outcome after angioplasty and stenting for symptomatic vertebral artery stenosis compared with medical treatment in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): a randomized trial. Stroke, 38, 1526–30.CrossRefGoogle ScholarPubMed
Dotter, CT, Judkins, MP, Rosch, J. (1967). Nonoperative treatment of arterial occlusive disease: a radiologically facilitated technique. Radiol Clin North Am, 5, 531–42.Google ScholarPubMed
Eberhardt, O, Naegele, T, Raygrotzki, S, Weller, M, Ernemann, U. (2006). Stenting of vertebrobasilar arteries in symptomatic atherosclerotic disease and acute occlusion: case series and review of the literature. J Vasc Surg, 43, 1145–54.CrossRefGoogle ScholarPubMed
Eckstein, H-H, Ringleb, P, Allenberg, J-R, Berger, J, Fraedrich, G, Hacke, W, et al. (2008). Results of the Stent-Protected Angioplasty versus Carotid Endarterectomy (SPACE) study to treat symptomatic stenoses at 2 years: a multinational, prospective, randomised trial. Lancet Neurol, 7, 893902CrossRefGoogle ScholarPubMed
Eckstein, H-H, Reiff, T, Ringleb, P, Jansen, O, Mansmann, U, Hacke, W. (2016). SPACE-2: a missed opportunity to compare carotid endarterectomy, carotid stenting, and best medical treatment in patients with asymptomatic carotid stenosis. Eur J Vasc Endovasc Surg, 51, 761–5. doi:10.1016/j.ejvs.2016.02.005.CrossRefGoogle Scholar
Ederle, J, Davagnanam, I, van der Worp, HB, Venables, GS, Lyrer, PA, Featherstone, RL, et al. (2013). Effect of white-matter lesions on the risk of periprocedural stroke after carotid artery stenting versus endarterectomy in the International Carotid Stenting Study (ICSS): a prespecified analysis of data from a randomised trial. Lancet Neurol, 12, 866–72.CrossRefGoogle ScholarPubMed
Ederle, J, Featherstone, RL, Brown, MM. (2009a). Long-term outcome of endovascular treatment versus medical care for carotid artery stenosis in patients not suitable for surgery and randomised in the Carotid and Vertebral Artery Transluminal Angioplasty study (CAVATAS). Cerebrovasc Dis, 28, 17. doi:10.1159/000215936.CrossRefGoogle Scholar
Ederle, J, Bonati, LH, Dobson, J, Featherstone, RL, Gaines, PA, Beard, JD. (2009b). Endovascular treatment with angioplasty or stenting versus endarterectomy in patients with carotid artery stenosis in the Carotid and Vertebral Artery Transluminal Angioplasty Study (CAVATAS): long-term follow-up of a randomised trial. Lancet Neurol, 8, 898907. doi:10.1016/S1474-4422(09)70228-5.CrossRefGoogle ScholarPubMed
Engelter, S, Lyrer, P (2003). Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy. Cochrane Database Syst Rev, 2. CD001458. doi:10.1002/14651858.CD001458.CrossRefGoogle ScholarPubMed
Engelter, S, Lyrer, P. (2004). Antiplatelet therapy for preventing stroke and other vascular events after carotid endarterectomy (Cochrane Corner). Stroke, 35, 1227–8CrossRefGoogle Scholar
European Carotid Surgery Trialists’ Collaborative Group. (1991). MRC European Carotid Surgery Trial. Interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. Lancet, 337, 1235–43.Google Scholar
European Carotid Surgery Trialists’ Collaborative Group. (1998). Randomised trial of endarterectomy for recently symptomatic carotid stenosis: final results of the MRC European Carotid Surgery Trial (ECST). Lancet, 351, 1379–87.Google Scholar
Feasby, TE, Quan, H, Ghali, WA. (2002). Hospital and surgeon determinants of carotid endarterectomy outcomes. Archiv Neurol, 59, 1877–81.CrossRefGoogle ScholarPubMed
Fields, WS, Maslenikov, V, Meyer, JS, Hass, WK, Remington, RD, MacDonald, M. (1970). Joint study of extracranial arterial occlusion. V. Progress report on prognosis following surgery or non- surgical treatment for transient cerebral ischaemic attacks and cervical carotid artery lesions. JAMA, 211, 19932003.CrossRefGoogle ScholarPubMed
GALA Trial Collaborative Group, Lewis, SC, Warlow, CP, Bodenham, AR, Colam, B, Rothwell, PM, Torgerson, D, et al. (2008). General anaesthesia versus local anaesthesia for carotid surgery (GALA): a multicentre, randomised controlled trial. Lancet, 372, 2132–42.Google ScholarPubMed
Goldstein, LB, Moore, WS, Robertson, JT, Chaturvedi, S. (1997). Complication rates for carotid endarterectomy: a call for action. Stroke, 28, 889–90.CrossRefGoogle Scholar
Gorelick, PB. (1993). Distribution of atherosclerotic cerebrovascular lesions. Effects of age, race, and sex. Stroke, 24, 116–19Google Scholar
Gray, WA, Hopkins, LN, Yadav, S, Davis, T, Wholey, M, Atkinson, R. (2006). Protected carotid stenting in high-surgical-risk patients: the ARCHeR results. J Vasc Surg, 44, 258–68. doi:10.1016/j.jvs.2006.03.044.CrossRefGoogle ScholarPubMed
Gray, WA, Yadav, JS, Verta, P, Scicli, A, Fairman, R, Wholey, M. (2007). The CAPTURE registry: predictors of outcomes in carotid artery stenting with embolic protection for high surgical risk patients in the early post-approval setting. Catheter Cardiovasc Interv, 70, 1025–33. doi:10.1002/ccd.21359.CrossRefGoogle ScholarPubMed
Grubb, Jr RL, Derdeyn, CP, Fritsch, SM, Carpenter, DA, Yundt, KD, Videen, TO, et al. (1998). Importance of hemodynamic factors in the prognosis of symptomatic carotid occlusion. JAMA, 280, 1055–60.CrossRefGoogle ScholarPubMed
Guimaraens, L, Sola, MT, Matali, A, Arbelaez, A, Delgado, M, Soler, L. (2002). Carotid angioplasty with cerebral protection and stenting: report of 164 patients (194 carotid percutaneous transluminal angioplasties). Cerebrovasc Dis, 13, 114–19.CrossRefGoogle Scholar
Gulli, G, Marquardt, L, Rothwell, PM, Markus, HS. (2013). Stroke risk after posterior circulation stroke/transient ischemic attack and its relationship to site of vertebrobasilar stenosis: pooled data analysis from prospective studies. Stroke, 44, 598604.CrossRefGoogle ScholarPubMed
Gurm, HS, Yadav, JS, Fayad, P, Katzen, BT, Mishkel, GJ, Bajwa, TK. (2008). Long-term results of carotid stenting versus endarterectomy in high-risk patients. N Engl J Med, 358, 1572–9. doi:10.1056/NEJMoa0708028.CrossRefGoogle ScholarPubMed
Heart Protection Study Collaborative Group. (2004). Effects of cholesterol-lowering with simvastatin on stroke and other major vascular events in 20,536 people with cerebrovascular disease or other high-risk conditions. Lancet, 363, 757–67.Google Scholar
Higgins, JP, Altman, DG, Gotzsche, PC, Juni, P, Moher, D, Oxman, AD. (2011). The Cochrane Collaboration’s tool for assessing risk of bias in randomised trials. BMJ, 343, d5928. doi:10.1136/bmj.d5928.CrossRefGoogle ScholarPubMed
Hoffmann, A, Taschner, C, Mendelowitsch, A, Merlo, A, Radue, EW. (2008). Carotid artery stenting versus carotid endarterectomy – a prospective randomised controlled single-centre trial with long-term follow-up (BACASS). Schweizer Archiv fur Neurologie und Psychiatrie, 159, 84–9.Google Scholar
Howard, G, Roubin, GS, Jansen, O, Hendrikse, J, Halliday, A, Fraedrich, G, et al. (2016). Association between age and risk of stroke or death from carotid endarterectomy and carotid stenting: a meta-analysis of pooled patient data from four randomised trials. Lancet, 387, 1305–11.CrossRefGoogle ScholarPubMed
International Carotid Stenting Study Investigators. (2010). Carotid artery stenting compared with endarterectomy in patients with symptomatic carotid stenosis (International Carotid Stenting Study): an interim analysis of a randomised controlled trial. Lancet, 375, 985–97.Google Scholar
Kuliha, M, Roubec, M, Prochazka, V. (2015). Randomized clinical trial comparing neurological outcomes after carotid endaterectomy or stenting. J Vasc Surg, 62, 519.CrossRefGoogle Scholar
Liem, MI, Kennedy, F, Bonati, LH, van der Lugt, A, Coolen, BF, Nederveen, A, et al. (2017). Investigations of carotid stenosis to identify vulnerable atherosclerotic plaque and determine individual stroke risk. Circ J, 81, 1246–53.CrossRefGoogle ScholarPubMed
Lin, PH, Bush, RL, Lubbe, DF, Cox, MM, Zhou, W, McCoy, SA. (2004). Carotid artery stenting with routine cerebral protection in high-risk patients. Am J Surg, 188, 644–52. doi:10.1016/j.amjsurg.2004.08.035.CrossRefGoogle ScholarPubMed
Ling, F. (2006). Preliminary report of trial of endarterectomy versus stenting for the treatment of carotid atherosclerotic stenosis in China (TESCAS-C). Chinese J Cerebrovasc Dis, 3, 48.Google Scholar
Liu, CW, Liu, B, Ye, W, Wu, WW, Li, YJ, Zheng, YH. (2009). Carotid endarterectomy versus carotid stenting: a prospective randomized trial. Zhonghua Wai Ke Za Zhi, 47, 267–70.Google ScholarPubMed
Lovett, JK, Coull, A, Rothwell, PM, on behalf of the Oxford Vascular Study. (2004). Early risk of recurrent stroke by aetiological subtype: implications for stroke prevention. Neurology, 62, 569–74.CrossRefGoogle Scholar
Lovett, J, Dennis, M, Sandercock, PAG, Bamford, J, Warlow, CP, Rothwell, PM. (2003). The very early risk of stroke following a TIA. Stroke, 34, e138e140.CrossRefGoogle Scholar
MacDonald, S, Evans, DH, Griffiths, PD, McKevitt, FM, Venables, GS, Cleveland, TJ, et al. (2010). Filter-protected versus unprotected carotid artery stenting: a randomised trial. Cerebrovasc Dis, 29, 282–9.CrossRefGoogle ScholarPubMed
Markus, HS, Droste, DW, Kaps, M, Larrue, V, Lees, K, Siebler, M, Ringelstein, EB (2005). Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection. The Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic carotid Stenosis (CARESS) trial. Circulation, 111, 2233–40.CrossRefGoogle ScholarPubMed
Markus, HS, Larsson, SC, Kuker, W, Schulz, UG, Ford, I, Rothwell, PM, Clifton, A; VIST Investigators. (2017). Stenting for symptomatic vertebral artery stenosis: The Vertebral Artery Ischaemia Stenting Trial. Neurology, 89, 1229–36.CrossRefGoogle ScholarPubMed
Markus, HS, van der Worp, HB, Rothwell, PM. (2013). Posterior circulation ischaemic stroke and transient ischaemic attack: diagnosis, investigation, and secondary prevention. Lancet Neurol, 12, 989–98.CrossRefGoogle ScholarPubMed
Mas, J-L, Chatellier, G, Beyssen, B, Branchereau, A, Moulin, T, Becquemin, JP, et al. (2006). Endarterectomy versus stenting in patients with symptomatic severe carotid stenosis. N Engl J Med, 355, 1660–71.CrossRefGoogle ScholarPubMed
Mas, JL, Arquizan, C, Calvet, D, Viguier, A, Albucher, JF, Piquet, P (2014). Long-term follow-up study of endarterectomy versus angioplasty in patients with symptomatic severe carotid stenosis trial. Stroke, 45, 2750–6. doi:10.1161/STROKEAHA.114.005671.CrossRefGoogle ScholarPubMed
Matsen, SL, Chang, DC, Perler, BA, Roseborough, GS, Williams, GM. (2006). Trends in the in-hospital stroke rate following carotid endarterectomy in California and Maryland. J Vasc Surg, 44, 488–95.CrossRefGoogle ScholarPubMed
Mayberg, MR, Wilson, E, Yatsu, F, Weiss, DG, Messina, L, Hershey, LA, et al. (1991). Carotid endarterectomy and prevention of cerebral ischemia in symptomatic carotid stenosis. Veterans Affairs Cooperative Studies Program 309 Trialist Group. JAMA, 266, 3289–94.CrossRefGoogle ScholarPubMed
Mercuri, M, Bond, MG, Sirtori, CR, Veglia, F, Crepaldi, G, Feruglio, FS, et al. (1996). Pravastatin reduces carotid intima-media thickness progression in an asymptomatic hypercholesterolemic Mediterranean population: the Carotid Atherosclerosis Italian Ultrasound Study. Am J Med, 101, 627–34.CrossRefGoogle Scholar
Molloy, J, Markus, HS. (1999). Asymptomatic embolization predicts stroke and TIA risk in patients with carotid artery stenosis. Stroke, 30, 1440–3.CrossRefGoogle ScholarPubMed
Morgenstern, LB, Fox, AJ, Sharpe, BL, Eliasziw, M, Barnett, HJ, Grotta, JC, for the North American Symptomatic Carotid Endarterectomy Trial (NASCET) Group. (1997). The risks and benefits of carotid endarterectomy in patients with near occlusion of the carotid artery. Neurology, 48, 911–15.CrossRefGoogle ScholarPubMed
Naylor, AR, Bolia, A, Abbott, RJ, Pye, IF, Smith, J, Lennard, N. (1998). Randomized study of carotid angioplasty and stenting versus carotid endarterectomy: a stopped trial. J Vasc Surg, 28, 326334.CrossRefGoogle ScholarPubMed
North American Symptomatic Carotid Endarterectomy Trial Collaborators. (1991a). Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade carotid stenosis. N Engl J Med, 325, 445–53.Google Scholar
North American Symptomatic Carotid Endarterectomy Trial Collaborators. (1991b). North American Symptomatic Carotid Endarterectomy Trial. Methods, patient characteristics, and progress. Stroke, 22, 711–20.Google Scholar
North American Symptomatic Carotid Endarterectomy Trial Collaborators (1998). Benefit of carotid endarterectomy in patients with symptomatic moderate or severe stenosis. N Engl J Med, 339, 1415–25.Google Scholar
Ogata, J, Masuda, J, Yutani, C, Yamaguchi, T. (1990). Rupture of atheromatous plaque as a cause of thrombotic occlusion of stenotic internal carotid artery. Stroke, 21, 1740–45.CrossRefGoogle ScholarPubMed
Orrapin, S, Rerkasem, K. (2017). Carotid endarterectomy for symptomatic carotid stenosis. Cochrane Database Syst Rev, 6. CD001081. doi:10.1002/14651858.CD001081.pub3.CrossRefGoogle ScholarPubMed
Paraskevas, KI, Robertson, V, Saratzis, AN, Naylor, AR. (2018). An updated systematic review and meta-analysis of outcomes following eversion vs. conventional carotid endarterectomy in randomised controlled trials and observational studies. Eur J Vasc Endovasc Surg, 55, 465–73. doi.org/10.1016/j.ejvs.2017.12.025CrossRefGoogle ScholarPubMed
Payne, DA, Jones, CI, Hayes, PD, Thompson, MM, London, NJ, Bell, PR, et al. (2004). Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation, 109, 1476–81.CrossRefGoogle ScholarPubMed
PROGRESS Collaborative Group. (2001). Randomised trial of a perindopril-based blood-pressure- lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet, 358, 1033–41.Google Scholar
Reimers, B, Corvaja, N, Moshiri, S, Sacca, S, Albiero, R, Di Mario, C. (2001). Cerebral protection with filter devices during carotid artery stenting. Circulation, 104, 1215.CrossRefGoogle ScholarPubMed
Reimers, B, Schluter, M, Castriota, F, Tubler, T, Corvaja, N, Cernetti, C. (2004). Routine use of cerebral protection during carotid artery stenting: results of a multicenter registry of 753 patients. Am J Med, 116, 217–22. doi:10.1016/j.amjmed.2003.09.043CrossRefGoogle ScholarPubMed
Rerkasem, K, Rothwell, PM. (2009). Patch angioplasty versus primary closure for carotid endarterectomy. Cochrane Database Syst Rev, 4. CD000160. doi:10.1002/14651858.CD000160.pub3.CrossRefGoogle ScholarPubMed
Rerkasem, K, Rothwell., PM (2010). Patches of different types for carotid patch angioplasty. Cochrane Database Syst Rev, 3. CD000071. doi:10.1002/14651858.CD000071.pub3.CrossRefGoogle ScholarPubMed
Ringleb, PA, Allenberg, J, Bruckmann, H, Eckstein, HH, Fraedrich, G, Hartmann, M. (2006). 30 day results from the SPACE trial of stent-protected angioplasty versus caro